Document:

Litigation Settlement Agreement

 Exhibit 10.32 
  
 LITIGATION SETTLEMENT AGREEMENT 
  
 This Litigation Settlement Agreement (“Agreement”) is entered into effective as of April 4, 2003 (“Effective Date”), by
and among: 
  
 Rita Medical Systems, Inc.
(“RITA”), a Delaware corporation, on the one hand, and 
  
 RadioTherapeutics Corporation (“RTC”), a California corporation, Boston Scientific Corporation (“BSC”), a Delaware corporation, Scimed Life Systems, Inc. (“Scimed”), a Minnesota
corporation, The Board of Regents of the University of Nebraska (“Board of Regents”), a Nebraska corporation, UneMed Corporation (“UneMed”), a Nebraska corporation, (together, the Board of Regents and UneMed are
referred to as “Nebraska”), University of Kansas d/b/a University of Kansas Medical Center (“KUMC”), a Kansas state educational institution and University of Kansas Medical Center Research Institute, Inc.
(“KUMCRI”), a Kansas corporation, (together, KUMC and KUMCRI are referred to as “Kansas”) (collectively, Nebraska and Kansas are referred to as the “Universities”), on the other hand; 
  
 (each of RITA, RTC, BSC, Scimed, Nebraska and Kansas are referred to as a
“Party” and collectively as the “Parties”). 
  
 RECITALS 
  
 A. There is
pending in the United States District Court for the Northern District of California Civil Action No. C01-03267, in which RITA is the plaintiff and 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 RTC is the defendant, for infringement of United States Patent Nos. 6,071,280, 5,935,123, 5,728,143, 5,683,384, 5,672,174
and 5,672,173 owned by RITA. 
  
 B. There is also pending in the
United States District Court for the Northern District of California Civil Action No. C02-01745, in which RTC, Scimed and Nebraska are the plaintiffs and RITA is the defendant, for infringement of United States Patent Nos. 5,855,576 and 6,454,765
owned by the Board of Regents, exclusively licensed to UneMed and exclusively sublicensed to RTC, and United States Patent No. 5,584,872 owned by Scimed. 
  
 C. There is also pending in the United States District Court for the Northern District of California Civil Action No. C02-03270, in which BSC and Kansas
are the plaintiffs and RITA is the defendant, for infringement of United States Patent No. Re. 35,330 owned by KUMC and exclusively (within limited fields of use) licensed to BSC. 
  
 D. There is also pending in the United States District Court for the Northern District of California Civil Action No.
C02-5005, in which RTC and Nebraska are the plaintiffs and RITA is the defendant, for patent interference. 
  
 E. There is also pending in Europe a certain appeal proceeding bearing Case No. T0700/02-322 (the “European Appeal”) against the Decision
of the Opposition Division of the European Patent Office dated April 17, 2002 in Opposition Proceedings Re European Patent No. EP 0 777 445 B1, formerly European Patent Application 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 No. 95928379.7-2305, in which RTC is the opponent and RITA is the applicant (the “Opposition”).

  
 F. It is the desire and intention of the Parties to avoid the
risks and expenses of further litigation of the Actions (as defined herein), to avoid disputes between themselves and to settle the rights, claims and demands between them relating to the subject matter of the Actions, without any admissions
whatsoever by any Party, upon the terms and conditions set forth in this Agreement. 
  
 NOW, THEREFORE, in consideration of the promises and mutual covenants and agreements contained here, the Parties agree as follows: 
  
 1. DEFINITIONS 
  
 1.1 “Actions” shall mean, collectively, the pending actions and the European Appeal and Opposition as described in Recitals
A through E of this Agreement. 
  
 1.2
“Affiliate” shall mean, with respect to any Person, any other Person that, directly or indirectly, controls, is controlled by or is under common control with, that Person, provided however, that in each case any
such other Person shall be considered to be an Affiliate only during the time during which such control exists. For purposes of this definition, “control”, including, with correlative meaning, the terms “controlled by” and
“under common control with”, as used with respect to any Person, shall mean the possession, directly or indirectly, of the power to direct and/or cause the direction of the 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise.

  
 1.3 “Claim” shall mean an
issued patent claim which has not expired and which has not been disclaimed, canceled or finally held invalid or unenforceable by a court of competent jurisdiction from which no further appeal is possible or has been taken within the time period
provided under applicable law for such an appeal. If an issued patent claim has been finally held unenforceable as provided in the immediately preceding sentence, but thereafter the unenforceability thereof is purged such that under applicable law
it again becomes enforceable, such patent claim shall thereafter be a Claim for purposes of the immediately preceding sentence. 
  
 1.4 “Existing Products” shall mean Products offered for sale or sold in the Field by an Original Party as of the Effective
Date. 
  
 1.5 “Field” shall mean
Products and Methods used to ablate tumors with radio frequency (RF) electrical energy. 
  
 1.6 “Future Products” shall mean Products, other than Existing Products, offered for sale or sold in the Field after the Effective Date. 
  
 1.7 “Gastro-Intestinal Tract” shall mean the
body passage beginning at the esophagus and including, but not limited to, the stomach, the small and large intestines and the rectum, through which food taken into the body is digested. 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 1.8 “Head and Neck Region” shall mean the interior and exterior regions of
the body located above the esophagus, including, but not limited to, the soft palate, uvula, tonsils, the nasal turbinates and facial tissue. 
  
 1.9 “LaFontaine Patent Portfolio” shall mean and include all of the issued and unexpired United States patents listed in
Exhibit A, as well as all United States and foreign patents that have issued or may hereafter issue on applications which claim the benefit of the priority filing date(s) of any such patents. 
  
 1.10 “LeVeen Everting Electrode Claims” shall
mean those Claims of any patents within the LeVeen Patent Portfolio which require for infringement an everting, RF emitting electrode, or its use. 
  
 1.11 “LeVeen Patent Portfolio” shall mean and include all of the issued and unexpired United States patents listed in
Exhibit B, as well as all United States and foreign patents that have issued or may hereafter issue on applications which claim the benefit of the priority filing date(s) of any such patents. 
  
 1.12 “Licensed Territories” shall mean the
United States and all foreign countries worldwide where a Claim of the subject Patent Portfolio has issued or does issue. 
  
 1.13 “Malone Patent Portfolio” shall mean and include all of the issued and unexpired United States patents listed in
Exhibit C, as well as all United States and 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 foreign patents that have issued or may hereafter issue on applications which claim the benefit of the priority filing
date(s) of any such patents. 
  
 1.14
“Method” shall mean any process or method. 
  
 1.15 “Net Sales” shall mean the aggregate amount of net sales recorded by the applicable Party (and its Affiliates) from sales of applicable Products in accordance with generally accepted accounting
principles, consistently applied by such Party across all similar product lines, in connection with the preparation of such Party’s financial statements, as publicly-reported. 
  
 1.16 “New Patents” shall mean and include any and all United States and foreign patents and
patent applications (i) having an earliest priority filing date after the Effective Date of this Agreement; (ii) that are acquired or licensed by a Party, or any of its respective Affiliates, from a Third Person after the Effective Date of this
Agreement; or (iii) that are owned, licensed or controlled, prior to the date of the subject acquisition, by a Third Person that acquires, whether by merger, purchase of assets, operation of law or in any other manner, any of RITA, RTC, Scimed, BSC,
or any of their respective Affiliates, after the Effective Date of this Agreement. 
  
 1.17 “Original Party” shall mean each of RITA, RTC, BSC, Scimed, Nebraska and Kansas and “Original Parties” shall mean all of those Parties, collectively. For the
avoidance of doubt, Affiliates, permitted successors and permitted assigns of the Original Parties to this Agreement are not, and shall not be deemed to be, Original Parties. 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 1.18 “Patent Portfolio” shall mean, as applicable, the LeVeen Patent
Portfolio, the RTC RF Ablation Patent Portfolio, the Malone Patent Portfolio, the LaFontaine Patent Portfolio, the RITA Patent Portfolio or the RITA Infusion Claims, as the context may require. 
  
 1.19 “Person” shall mean an individual or any
legally recognized entity, including any corporation, partnership, limited partnership, limited liability company, association or trust. 
  
 1.20 “Product” shall mean any system, apparatus or component thereof. 
  
 1.21 “Regulatory Authority” shall mean the
U.S. Food and Drug Administration and any equivalent national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental or quasi-governmental entity outside of the United States.

  
 1.22 “Reserved Areas” shall
mean any Product which, in the absence of a right or license, would infringe one or more of the Claims of any patent within the Malone Patent Portfolio and that is specially made or adapted for use, or the use of such Product, in the following
anatomical fields of use: (i) the Head and Neck Regions; (ii) the Gastro-Intestinal Tract; (iii) the Spine; and/or (iv) cardiovascular applications. 
  
 1.23 “RITA Infusion Claims” shall mean those Claims of any patents within the RITA Patent Portfolio which require for
infringement liquid infusion capability or the use of liquid infusion. 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 1.24 “RITA Patent Portfolio” shall mean and include all United States
patent applications and all issued and unexpired United States patents owned or controlled by RITA as of the Effective Date or as to which RITA has the right to grant licenses or sub-licenses as of the Effective Date, including, without limitation,
those United States patent applications and patents listed in Exhibit D, as well as all United States and foreign patents that have issued or may hereafter issue on applications which claim the benefit of the priority filing date(s) of any
such patent applications and patents. 
  
 1.25
“RITA Temperature Sensor Claims” shall mean those Claims of any patents within the RITA Patent Portfolio which require for infringement at least one temperature-sensing device integrally located on an ablation device, or
the use of such ablation device. 
  
 1.26 “RTC
Impedance Display Claims” shall mean those Claims of any patents within the RTC RF Ablation Patent Portfolio which require for infringement the display of impedance or the use of displayed impedance. 
  
 1.27 “RTC RF Ablation Patent Portfolio” shall
mean and include all United States patent applications and all issued and unexpired United States patents owned or controlled by RTC as of the time of its acquisition by BSC or as to which RTC had the right as of such time to grant licenses or
sub-licenses (excluding the LeVeen Patent Portfolio), including, without limitation, those United States patent applications and patents listed in Exhibit E, as well as all United States and foreign patents that have 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 issued or may hereafter issue on applications which claim the benefit of the priority filing date(s) of any such patent
applications and patents. 
  
 1.28
“Spine” shall mean the skeletal structures and structures in and above the vertebral column from the occipital region to the sacral region of the spine including the bony structures and associated soft tissue, but
excluding the nasopharynx and non-spine structures. 
  
 1.29
“Sub-Field” shall mean tumor ablation within the Field directed to specific organs or regions of the body. 
  
 1.30 “Third Person” shall mean a Person other than the Parties or any of their respective Affiliates. 
  
 2. LICENSE GRANTS 
  
 2.1 License Grant to RITA under LeVeen Patent Portfolio. Subject to the terms and conditions of this
Agreement, including, without limitation, the limitations set forth in Section 2.2, and in consideration of the payment of license fees to Nebraska in accordance with Section 3.1, each of Nebraska and RTC hereby grants to RITA and RITA’s
Affiliates, under the LeVeen Patent Portfolio, but excluding the LeVeen Everting Electrode Claims, a non-exclusive license throughout the Licensed Territories in the Field to make, have made, use, practice, import, offer to sell, sell and otherwise
dispose of or make available for use, directly or indirectly, Products and Methods which, but for the license granted herein, would infringe one or more of the Claims within the LeVeen 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 Patent Portfolio, excluding the LeVeen Everting Electrode Claims. Notwithstanding any other provision of this Agreement,
the foregoing license extends only to such Products and Methods as are offered for sale, sold and otherwise disposed of or made available for use under RITA’s (or its Affiliates’) own trademarks, tradenames and/or label(s), which shall be
the most prominent trademarks, tradenames and/or label(s) thereon, and does not extend, and shall not be construed to extend, to any Products, or parts or components thereof, offered for sale, sold or otherwise disposed of or made available
for use to any Third Person by RITA (or its Affiliates) for resale or re-distribution by such Third Person solely under such Third Person’s own trademarks, tradenames and/or label(s). Subject to Section 3.1, the foregoing license grant is fully
paid and [***]. 
  
 2.2 Limitations on License under
LeVeen Patent Portfolio. Nothing in this Agreement shall be construed to grant RITA or its Affiliates the right to sublicense the LeVeen Patent Portfolio, or any of RITA’s (or its Affiliates’) license rights hereunder, and any such
sublicensing is strictly prohibited. RITA, on its own behalf and on behalf of its Affiliates, hereby acknowledges that: (i) the rights and licenses granted by Nebraska and RTC to RITA and its Affiliates are non-exclusive, and (ii) nothing in this
Agreement shall limit or restrict Nebraska’s and/or RTC’s rights to grant similar rights and licenses to one or more additional Persons within the Licensed Territories, or to exercise such rights themselves. RITA, on its own behalf and on
behalf of its Affiliates, further acknowledges and agrees that the license granted under Section 2.1 does not include, and expressly excludes, the grant of any rights with respect to the LeVeen Everting Electrode Claims. Notwithstanding the
foregoing, RITA shall be permitted to 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 sell and otherwise make available, directly, or indirectly through distributors, solely for use in Japan, the existing
inventory of Model 30 arrays as of the Effective Date (“Japan Inventory”). RITA acknowledges and agrees that the number of units comprising the Japan Inventory does not exceed six hundred (600) units. 
  
 2.3 License Grant to RITA under RTC RF Ablation Patent
Portfolio. Subject to the terms and conditions of this Agreement, including, without limitation, the limitations set forth in Section 2.4, RTC hereby grants to RITA and RITA’s Affiliates, under the RTC RF Ablation Patent Portfolio, but
excluding the RTC Impedance Display Claims, a non-exclusive license throughout the Licensed Territories in the Field to make, have made, use, practice, import, offer to sell, sell and otherwise dispose of or make available for use, directly or
indirectly, Products and Methods which, but for the license granted herein, would infringe one or more of the Claims within the RTC RF Ablation Patent Portfolio, excluding the RTC Impedance Display Claims. Notwithstanding any other provision of this
Agreement, the foregoing license extends only to such Products and Methods as are offered for sale, sold and otherwise disposed of or made available for use under RITA’s (or its Affiliates’) own trademarks, tradenames and/or label(s),
which shall be the most prominent trademarks, tradenames and/or label(s) thereon, and does not extend, and shall not be construed to extend, to any Products, or parts or components thereof, offered for sale, sold or otherwise disposed of or
made available for use to any Third Person by RITA or its Affiliates for resale or re-distribution by such Third Person solely under such Third Person’s own trademarks, tradenames and/or label(s). The foregoing license grant is fully paid and
[***]. 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 2.4 Limitations on License under RTC RF Ablation Patent Portfolio. Nothing in this
Agreement shall be construed to grant RITA or its Affiliates the right to sublicense the RTC RF Ablation Patent Portfolio, or any of RITA’s (or its Affiliates’) license rights hereunder, and any such sublicensing is strictly prohibited.
RITA, on its own behalf and on behalf of its Affiliates, hereby acknowledges that: (i) the rights and licenses granted by RTC to RITA and its Affiliates are non-exclusive, and (ii) nothing in this Agreement shall limit or restrict RTC’s rights
to grant similar rights and licenses to one or more additional Persons within the Licensed Territories, or to exercise such rights itself. RITA, on its own behalf and on behalf of its Affiliates, further acknowledges and agrees that the license
granted under Section 2.3 does not include, and expressly excludes, the grant of any rights with respect to the RTC Impedance Display Claims. Notwithstanding the foregoing, RITA shall be permitted to make, have made, use, practice, import,
offer to sell, sell and otherwise make available for use RITA’s Existing Products for a period of eighteen (18) months (as may be adjusted pursuant to Section 4.8) after the Effective Date subject to and in accordance with the terms and
conditions of RITA’s covenants set forth in Section 4.8. 
  
 2.5 License Grant to RITA under Malone Patent Portfolio. Subject to the terms and conditions of this Agreement, including, without limitation, the limitations set forth in Section 2.6, and in consideration of the
payment of license fees to Kansas in accordance with Section 3.1, each of Kansas and BSC hereby grants to RITA and RITA’s Affiliates, under the Malone Patent Portfolio, a non-exclusive license throughout the Licensed Territories in the Field to
make, have made, use, practice, import, offer to sell, 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 sell and otherwise dispose of or make available for use, directly or indirectly, Products and Methods which, but for the
license granted herein, would infringe one or more of the Claims within the Malone Patent Portfolio, but excluding any Products within the Reserved Areas. Notwithstanding any other provision of this Agreement, the foregoing license extends only to
such Products and Methods as are offered for sale, sold and otherwise disposed of or made available for use under RITA’s (or its Affiliates’) own trademarks, tradenames and/or label(s), which shall be the most prominent trademarks,
tradenames and/or label(s) thereon, and does not extend, and shall not be construed to extend, to any Products, or parts or components thereof, offered for sale, sold or otherwise disposed of or made available for use to any Third Person by
RITA or its Affiliates for resale or re-distribution by such Third Person solely under such Third Person’s own trademarks, tradenames and/or label(s). Subject to Section 3.1, the foregoing license grant is fully paid and [***].

  
 2.6 Limitations on License under Malone Patent
Portfolio. Nothing in this Agreement shall be construed to grant RITA or its Affiliates the right to sublicense the Malone Patent Portfolio, or any of RITA’s (or its Affiliates’) license rights hereunder, and any such sublicensing
is strictly prohibited. RITA, on its own behalf and on behalf of its Affiliates, hereby acknowledges that: (i) the rights and licenses granted by Kansas and BSC to RITA and its Affiliates are non-exclusive, and (ii) nothing in this Agreement shall
limit or restrict Kansas’ and/or BSC’s rights to grant similar rights and licenses to one or more additional Persons within the Licensed Territories, or to exercise such rights themselves. RITA, on its own behalf and on behalf of its
Affiliates, further 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 acknowledges and agrees that the license granted under Section 2.5 does not include, and expressly excludes, the
grant of any rights with respect to Products within the Reserved Areas. 
  
 2.7 License Grant to RITA under LaFontaine Patent Portfolio. Subject to the terms and conditions of this Agreement, including, without limitation, the limitations set forth in Section 2.8, Scimed hereby grants to RITA
and RITA’s Affiliates, under the LaFontaine Patent Portfolio, a non-exclusive license throughout the Licensed Territories in the Field to make, have made, use, practice, import, offer to sell, sell and otherwise dispose of or make available for
use, directly or indirectly, Products and Methods which, but for the license granted herein, would infringe one or more of the Claims within the LaFontaine Patent Portfolio. Notwithstanding any other provision of this Agreement, the foregoing
license extends only to such Products and Methods as are offered for sale, sold and otherwise disposed of or made available for use under RITA’s (or its Affiliates’) own trademarks, tradenames and/or label(s), which shall be the most
prominent trademarks, tradenames and/or label(s) thereon, and does not extend, and shall not be construed to extend, to any Products, or parts or components thereof, offered for sale, sold or otherwise disposed of or made available for use to
any Third Person by RITA or its Affiliates for resale or re-distribution by such Third Person solely under such Third Person’s own trademarks, tradenames and/or label(s). The foregoing license grant is fully paid and [***]. 

 
 2.8 Limitations on License under LaFontaine Patent
Portfolio. Nothing in this Agreement shall be construed to grant RITA or its Affiliates the right to sublicense 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 the LaFontaine Patent Portfolio, or any of RITA’s (or its Affiliates’) license rights hereunder, and any such
sublicensing is strictly prohibited. RITA, on its own behalf and on behalf of its Affiliates, hereby acknowledges that: (i) the rights and licenses granted by Scimed to RITA and its Affiliates are non-exclusive, and (ii) nothing in this Agreement
shall limit or restrict Scimed’s rights to grant similar rights and licenses to one or more additional Persons within the Licensed Territories, or to exercise such rights itself. 
  
 2.9 License Grant to BSC under the RITA Patent Portfolio. Subject to the terms and conditions of this
Agreement, including, without limitation, the limitations set forth in Section 2.10, RITA hereby grants to BSC and BSC’s Affiliates, under the RITA Patent Portfolio, but excluding the RITA Infusion Claims and RITA Temperature Sensor Claims, a
non-exclusive license throughout the Licensed Territories in the Field to make, have made, use, practice, import, offer to sell, sell and otherwise dispose of or make available for use, directly or indirectly, Products and Methods which, but for the
license granted herein, would infringe one or more of the Claims within the RITA Patent Portfolio, excluding the RITA Infusion Claims or the RITA Temperature Sensor Claims. Notwithstanding any other provision of this Agreement, the foregoing license
extends only to such Products and Methods as are offered for sale, sold and otherwise disposed of or made available for use under BSC’s (or its Affiliates’) own trademarks, tradenames and/or label(s), which shall be the most prominent
trademarks, tradenames and/or label(s) thereon, and does not extend, and shall not be construed to extend, to any Products, or parts or components thereof, offered for sale, sold or otherwise disposed of or made 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
available for use to any Third Person by BSC or its Affiliates for resale or re-distribution by such Third Person solely under such Third Person’s own
trademarks, tradenames and/or label(s). The foregoing license grant is fully paid and [***]. 
  
 2.10 Limitations on Licenses under RITA Patent Portfolio. Nothing in this Agreement shall be construed to grant BSC or its Affiliates, the
right to sublicense the RITA Patent Portfolio, or any of BSC’s (or its Affiliates’) license rights hereunder, and any such sublicensing is strictly prohibited. BSC, on its own behalf and on behalf of its Affiliates, hereby acknowledges
that: (i) the rights and licenses granted by RITA to BSC and its Affiliates under the RITA Patent Portfolio are non-exclusive, and (ii) nothing in this Agreement shall limit or restrict RITA’s rights to grant similar rights and licenses to one
or more additional Persons within the Licensed Territories, or to exercise such rights itself. BSC, on its own behalf and on behalf of its Affiliates, further acknowledges and agrees that the licenses granted under Section 2.9 do not include,
and expressly exclude, the grant of any rights with respect to the RITA Infusion Claims or the RITA Temperature Sensor Claims. 
  
 2.11 License Grant to BSC under the RITA Infusion Claims. Subject to the terms and conditions of this Agreement, including, without
limitation, the limitations set forth in Section 2.12, and in consideration of the payment of royalties by BSC to RITA in accordance with Section 3.3, RITA hereby grants to BSC and BSC’s Affiliates, under the RITA Infusion Claims, a
non-exclusive license throughout the Licensed Territories in the Field to make, have made, use, practice, import, offer to sell, sell and otherwise dispose of or make available for use, directly or indirectly, Products and Methods which, but for

  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
the license granted herein, would infringe any one or more of the RITA Infusion Claims. Notwithstanding any other provision of this Agreement: 
  
 (a) the foregoing license extends only to such Products and Methods
as are offered for sale, sold and otherwise disposed of or made available for use under BSC’s (or its Affiliates’) own trademarks, tradenames and/or label(s), which shall be the most prominent trademarks, tradenames and/or label(s)
thereon, and does not extend, and shall not be construed to extend, to any Products, or parts or components thereof, offered for sale, sold or otherwise disposed of or made available for use to any Third Person by BSC or its Affiliates for
resale or re-distribution by such Third Person solely under such Third Person’s own trademarks, tradenames and/or label(s); and 
  
 (b) BSC, on behalf of itself and its Affiliates, hereby covenants and agrees not to market, offer for sale or sell any Products or Methods that,
absent the foregoing license, would infringe the RITA Infusion Claims, until eighteen (18) months after the Effective Date. 
  
 2.12 Limitations on Licenses under RITA Infusion Claims. Nothing in this Agreement shall be construed to grant BSC or its Affiliates
the right to sublicense the RITA Infusion Claims, or any of BSC’s (or its Affiliates’) license rights hereunder, and any such sublicensing is strictly prohibited. BSC, on its own behalf and on behalf of its Affiliates, hereby acknowledges
that: (i) the rights and licenses granted by RITA to BSC and its Affiliates under the RITA Infusion Claims are non-exclusive, and (ii) nothing in this Agreement shall limit or restrict RITA’s rights to grant similar rights and licenses to

  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
one or more additional Persons within the Licensed Territories, or to exercise such rights itself. 
  
 2.13 No Licenses under New Patents. Each Party hereby
acknowledges and agrees that no right or license is granted to such Party under or in relation to this Agreement, whether expressly, by implication, estoppel or otherwise, by any other Party in regard to any New Patents of such other Party.

  
 2.14 Third Party IP Sublicenses Optional.
To the extent sublicenses to intellectual property rights granted by any third party license are made available to RITA (and RITA’s Affiliates) under Section 2.3 or to BSC (and BSC’s Affiliates) (individually, each a “Sublicensee
Party”) under Section 2.9, such sublicenses shall be optional at the sole discretion of the respective Sublicensee Party, will be limited to the terms of such third party license to the extent of the licenses granted hereunder, and such
Sublicensee Party shall pay any fees, royalties or other charges, of which it is made aware in a timely manner, resulting from such Party’s exercise of the sublicense rights granted herein. For avoidance of doubt, RITA (and its Affiliates) and
BSC (and its Affiliates) shall have the option to decline to include in the license granted to it herein any third party sublicense for which it does not want to pay the applicable fees, royalties or other charges or abide by other terms or
limitations applicable to sublicensees of such third party sublicense. With respect to any third party rights sublicensed hereunder, if the Sublicensee Party materially breaches its obligation to pay any applicable fees, royalties or other charges
or to abide by other terms or limitations applicable to it as a Sublicensee Party (of which it has been made aware in advance) as described above, the respective sublicense granted 

  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
herein may be terminated only with respect to such third party license (for which such obligations have been breached) upon sixty (60) days written notice,
unless such breach is cured within the notice period. 
  
 3. PAYMENT

  
 3.1 License Fee. The Parties enter
into this Agreement, and grant the license rights set forth herein, for and in consideration of, among other things, the payment by RITA to the Universities of the aggregate sum of Two Million, Six Hundred Fifty Thousand Dollars (US$2,650,000), as a
one-time fully paid up license fee and royalty in respect of the LeVeen Patent Portfolio and the Malone Patent Portfolio. This sum shall be paid by RITA to Nebraska and Kansas by wire transfers in immediately available funds in the sums of
US$1,325,000 and US$1,325,000 payable in accordance with the instructions set forth on Exhibit F within fourteen (14) days after the Effective Date of this Agreement. 
  
 3.2 Acknowledgement. Each of the Universities, RTC and BSC hereby acknowledges and agrees that the
payment by RITA to the Universities in accordance with Section 3.1 satisfies and fully discharges any and all liability on the part of either RTC or BSC pursuant to any royalty or other payment obligations under any respective license or sub-license
agreements between Nebraska and RTC and/or Kansas and BSC to pay any amount to either of the Universities as a consequence of the licenses granted to RITA under Sections 2.1 and 2.5. 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 3.3 Potential Royalties Regarding RITA Infusion Claims. In consideration of the
license grants set forth in Section 2.11 with respect to the RITA Infusion Claims, subject to the terms and conditions of this Agreement, from the Effective Date of this Agreement until the expiration of the last to expire of the RITA Infusion
Claims, BSC shall pay to RITA a royalty equal to [***] of the Net Sales in the Licensed Territories by or on behalf of BSC or its Affiliates to Third Persons of tumor ablation probes utilizing infusion which, but for the license granted
herein, would infringe any one or more of the RITA Infusion Claims issued in the Licensed Territories. 
  
 3.4 Statements and Payments. BSC, on behalf of itself and its Affiliates, shall deliver a quarterly statement to RITA indicating the
royalty payments due to RITA in respect of each calendar quarter accompanied by payment of the applicable royalty due. Each quarterly statement shall state the Net Sales in the Licensed Territories of tumor ablation probes utilizing infusion which,
but for the license granted herein, would infringe any one or more of the RITA Infusion Claims issued in the Licensed Territories, by BSC and its Affiliates to Third Persons for such calendar quarter. The first such statement shall be due prior to
the expiration of sixty (60) days after the close of the first calendar quarter following the first sale of such a tumor ablation probe to a Third Person in the Licensed Territories by BSC or any of its Affiliates. Subsequent statements shall be due
prior to the expiration of sixty (60) days following the close of each subsequent calendar quarter thereafter. Each such statement shall clearly state in reasonable detail the basis for calculating the royalty due to RITA during the applicable
calendar quarter. 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 3.5 Audits. BSC, on behalf of itself and its Affiliates, agrees to keep, in
accordance with its usual and customary practice and as set forth below, books of account and records of Net Sales in the Licensed Territories of those tumor ablation probes which are subject to the royalty obligations of Section 3.3. BSC, on behalf
of itself and its Affiliates, grants to RITA, at RITA’s expense, the right, exercisable no more than once during each calendar year, and subject to the execution of, and compliance with, a confidentiality agreement in form and substance
reasonably satisfactory to BSC, to examine such books and records at the location of such books and records on prior written notice of at least ten (10) business days, insofar as they concern the sale of applicable royalty-bearing tumor ablation
probes, for the purpose of verifying the amount of Net Sales in the Licensed Territories of such probes. Any such examination of books and records concerning the Net Sales of such probes shall be completed within fifteen (15) business days of the
date on which access to such books and records is made available to RITA. Nothing in this Section 3.5 shall be deemed to require BSC or its Affiliates to keep any books of account or records other than those which BSC or its Affiliates maintains in
the ordinary course of business in BSC’s or its Affiliates’ usual and customary practice, to retain any such books of account or records for any period in excess of the period for which BSC or its Affiliates’ retains such books and
records in the ordinary course of business in BSC’s or its Affiliates’ usual and customary practice, or to provide access to any books and records of BSC or its Affiliates other than as specified herein. 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 3.6 Nondisclosure. RITA shall hold the statements and reports described in Section
3.4 and any information acquired during any inspection and audit conducted in accordance with Section 3.5 in strict confidence and shall use such statements, reports and information solely for the purposes of (i) collecting any royalties due RITA,
and/or (ii) complying with the terms and conditions of this Agreement. Nothing in this Section 3.6 shall be construed to preclude RITA from making any disclosures required by any governmental laws or regulations or by judicial process. 

 
 4. RELEASES AND COVENANTS NOT TO SUE; ADDITIONAL COVENANTS. 
  
 4.1 Release by BSC, RTC, Scimed, Nebraska and Kansas in Favor
of RITA. Subject to the terms and conditions of this Agreement, each of BSC, RTC, Scimed, Nebraska and Kansas, for itself and for its respective Affiliates, and for all of its and their respective present and past officers, directors,
shareholders, agents, employees, attorneys and legal representatives, and each of them, hereby releases, acquits, discharges and covenants not to sue RITA, its Affiliates and all of its and their respective present and past officers, directors,
shareholders, agents, employees, suppliers, vendors, distributors, customers, attorneys and legal representatives, and each of them (collectively, the “RITA Releasees”), from or for: 
  
 (a) any claims, known or unknown, of infringement or violation of any
of the LeVeen Patent Portfolio, the RTC RF Ablation Patent Portfolio, the Malone Patent Portfolio or the LaFontaine Patent Portfolio, arising from, relating to, based on or 

  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
otherwise concerning Products or Methods made, have made, used, practiced, imported, offered for sale, sold or otherwise disposed of or made available for
use, directly or indirectly, by RITA or its Affiliates in the Field prior to the Effective Date; and 
  
 (b) any and all claims, demands, suits, damages, indebtedness, liabilities, actions and causes of action, whether known or unknown, whether legal,
equitable or administrative that are or may be based in whole or in part on, or do or may arise out of, or may be related to or based on or in any way connected with the Actions, or the facts, events, circumstances, actions and transactions that are
or could have been alleged in the Actions, or any matter referred to in the pleadings or any other papers filed or served in the Actions, excepting only the duties and obligations set forth in this Agreement. 
  
 4.2 Release by RITA in Favor of BSC. Subject to the
terms and conditions of this Agreement, RITA, for itself and for its Affiliates and for all of its and their present and past officers, directors, shareholders, agents, employees, attorneys and legal representatives (collectively, “RITA
Releasers”), hereby releases, acquits, discharges and covenants not to sue BSC, its Affiliates and all of its and their respective present and past officers, directors, shareholders, agents, employees, suppliers, vendors, distributors,
customers, attorneys and legal representatives, and each of them (collectively, the “BSC Releasees”), from or for: 
  
 (a) any claims, known or unknown, of infringement or violation of the RITA Patent Portfolio arising from, relating to, based on or otherwise
concerning 

  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
Products or Methods made, have made, used, practiced, imported, offered for sale, sold or otherwise disposed of or made available for use, directly or
indirectly, by BSC or its Affiliates in the Field prior to the Effective Date; and 
  
 (b) any and all claims, demands, suits, damages, indebtedness, liabilities, actions and causes of action, whether known or unknown, whether legal, equitable or administrative that are or may be based in whole
or in part on, or do or may arise out of, or may be related to or based on or in any way connected with the Actions, or the facts, events, circumstances, actions and transactions that are or could have been alleged in the Actions, or any matter
referred to in the pleadings or any other papers filed or served in the Actions, excepting only the duties and obligations set forth in this Agreement. 
  
 4.3 Release by RITA in Favor of Nebraska and Kansas. Subject to the terms and conditions of this Agreement, RITA, for itself and for
the RITA Releasers, hereby releases, acquits, discharges and covenants not to sue Nebraska and Kansas, and their respective Affiliates, and all of their respective present and past officers, directors, shareholders, agents, employees, suppliers,
vendors, distributors, customers, attorneys and legal representatives, and each of them, from or for: 
  
 (a) any claims, known or unknown, of infringement or violation of the RITA Patent Portfolio arising from, relating to, based on or otherwise concerning
Products or Methods made, have made, used, practiced, imported, offered for sale, sold or otherwise disposed of or made available for use, directly or indirectly, by Nebraska and Kansas, and their respective Affiliates in the Field prior to the
Effective Date; and 

  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 (b) any and all claims, demands, suits, damages, indebtedness, liabilities, actions and causes of action,
whether known or unknown, whether legal, equitable or administrative that are or may be based in whole or in part on, or do or may arise out of, or may be related to or based on or in any way connected with the Actions, or the facts, events,
circumstances, actions and transactions that are or could have been alleged in the Actions, or any matter referred to in the pleadings or any other papers filed or served in the Actions, excepting only the duties and obligations set forth in this
Agreement. 
  
 4.4 Waiver. Each Party, for
itself and for its respective Affiliates, expressly waives any and all rights under Section 1542 of the Civil Code of the State of California, and under any statute of similar import or purpose of any other jurisdiction. Section 1542 provides as
follows: 
  
 A GENERAL RELEASE DOES NOT EXTEND TO

  
 CLAIMS WHICH THE CREDITOR DOES NOT KNOW

  
 OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME

  
 OF EXECUTING THE RELEASE, WHICH IF KNOWN

  
 BY HIM MUST HAVE MATERIALLY AFFECTED HIS

  
 SETTLEMENT WITH THE DEBTOR. 
  
 4.5 Covenant Not to Sue by BSC, RTC and Scimed in Favor of
RITA. Subject to the terms and conditions of this Agreement, each of BSC, RTC and Scimed, for itself and for its respective Affiliates, hereby covenants not to sue RITA, or any of the 

  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
RITA Releasees, for infringement of any Claims owned or controlled by BSC, RTC or Scimed, or their respective Affiliates, by: 
  
 (a) Existing Products of RITA or its Affiliates, or 
  
 (b) Future Products of RITA or its Affiliates; 
  
 provided, however, that the foregoing covenant not to sue with respect to Future
Products of RITA or its Affiliates shall not apply to infringement of any Claim: 
  
 (i) within any New Patents of BSC, RTC or Scimed, or their respective Affiliates; 
  
 (ii) within the LeVeen Everting Electrode Claims; 
  
 (iii) within the RTC Impedance Display Claims; or 
  
 (iv) that requires for infringement any feature that is not substantially similar in all material aspects and application to an existing feature
in an Existing Product of RITA or its Affiliates, or the use thereof. 
  
 By way of example, and not by way of limitation, the foregoing covenant not to sue with respect to Future Products of RITA or its Affiliates shall not apply to Products which, in the absence of a right or license, would infringe one
or more Claims of BSC, RTC or Scimed (or their respective Affiliates) covering technologies (such as imaging or drug delivery) which are not substantially similar in all material aspects and application to a feature in an Existing Product of RITA or
its Affiliates, regardless of whether or not 

  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
such Claims also require for infringement a feature that is substantially similar in all material aspects and application to a feature of an Existing Product
of RITA or its Affiliates. 
  
 Notwithstanding any other provision
of this Agreement, the foregoing covenant extends only to such Products as are offered for sale, sold and otherwise disposed of or made available for use under RITA’s (or its Affiliates’) own trademarks, tradenames and/or label(s), which
shall be the most prominent trademarks, tradenames and/or label(s) thereon, and does not extend, and shall not be construed to extend, to any Products, or parts or components thereof, offered for sale, sold or otherwise disposed of or made
available for use to any Third Person by RITA (or its Affiliates) for resale or re-distribution by such Third Person solely under such Third Person’s own trademarks, tradenames and/or label(s). 
  
 4.6 Covenant Not to Sue by RITA in Favor of BSC. Subject
to the terms and conditions of this Agreement, including the payment by BSC of BSC’s royalty obligations under Section 3.3, RITA, for itself and for its respective Affiliates, hereby covenants not to sue BSC, or any of the BSC Releasees, for
infringement of any Claims owned or controlled by RITA, or its Affiliates, by: 
  
 (a) Existing Products of BSC or its Affiliates, or 
  
 (b) Future Products of BSC or its Affiliates; 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
provided, however, that the foregoing covenant not to sue with respect to Future Products of BSC or its Affiliates shall not apply to
infringement of any Claim: 
  
 (i) within any New Patents
of RITA, or its Affiliates; 
  
 (ii) within the RITA
Temperature Sensor Claims; or 
  
 (iii) that requires for
infringement any feature that is not substantially similar in all material aspects and application to an existing feature in an Existing Product of BSC or its Affiliates, or the use thereof. 
  
 Notwithstanding any other provision of this Agreement, the foregoing license extends only to
such Products as are offered for sale, sold and otherwise disposed of or made available for use under BSC’s (or its Affiliates’) own trademarks, tradenames and/or label(s), which shall be the most prominent trademarks, tradenames and/or
label(s) thereon, and does not extend, and shall not be construed to extend, to any Products, or parts or components thereof, offered for sale, sold or otherwise disposed of or made available for use to any Third Person by BSC (or its
Affiliates) for resale or re-distribution by such Third Person solely under such Third Person’s own trademarks, tradenames and/or label(s). 
  
 4.7 Additional Covenants Relating to Malone Patent Portfolio. In the event, and solely to the extent, that any of BSC, RTC or RITA
(or their respective Affiliates) (as applicable, the “Acquiring Party”) acquires any additional field-of-use license(s) after the Effective Date with respect to Products or Methods which, in the absence of a right or license, would
infringe any Claim within the Malone Patent 

  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
Portfolio that requires for infringement the use of RF electrical energy to ablate tumors, or the use of such Products or Methods to ablate tumors using RF
electrical energy, in the following anatomical fields of use: (i) the Head and Neck Regions; (ii) the Gastro-Intestinal Tract; or (iii) the Spine, then the Acquiring Party, for itself and for its respective Affiliates, hereby covenants not to sue
(A) if either BSC or RTC, or their respective Affiliates, is the Acquiring Party, RITA and the RITA Releasees, or (B) if RITA or its Affiliates is the Acquiring Party, each of BSC and RTC and the BSC Releasees, (in each case, as applicable, the
“Other Party”), for infringement of the Acquiring Party’s rights under such additional field-of-use license(s) by: 
  
 (a) Existing Products of the Other Party or its Affiliates, or 
  
 (b) Future Products of the Other Party or its Affiliates; 
  
 provided, however, that the foregoing covenant not to sue with respect to Future
Products of the Other Party or its Affiliates shall not apply to infringement of any Claim that requires for infringement any feature that is not substantially similar in all material aspects and application to an existing feature in an
Existing Product of the Other Party or its Affiliates, or the use thereof. 
  
 4.8 Additional Covenant by RITA. In consideration for the licenses granted to RITA under this Agreement, the foregoing releases and covenants not to sue under this Section 4, and so as not to
induce or contribute to infringement of the RTC Impedance Display Claims, effective from the Effective Date until the expiration of the last-to-expire 

  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
of the Claims within the RTC Impedance Display Claims, RITA, for itself and for its Affiliates, hereby covenants and agrees: 
  
 (a) not to knowingly promote or support through customer marketing
efforts, either directly or through RITA’s agents or distributors, the use of impedance on or in the performance of RITA’s (or its Affiliates’) Products in the Field; and 
  
 (b) not to display impedance, in regard to the use of RITA’s (or its Affiliates’) Products made, have made,
used, practiced, imported, offered for sale, sold or otherwise disposed of or made available for use in the Field, 
  
 provided, however, that RITA (and its Affiliates) may: (i) at all times educate customers of RITA (or its Affiliates) on the use of RITA’s (or its
Affiliates’) Products through non-promotional materials (such as directions for use, instructions for use and training materials, but not including brochures, sales aids, speeches, articles, reprints of articles or other marketing literature),
(ii) notwithstanding the foregoing, distribute customer marketing literature promoting the use of impedance on Existing Products of RITA or its Affiliates for up to six (6) months after the Effective Date, and (iii) display impedance on any of the
Existing Products of RITA or its Affiliates sold up to the eighteen (18) month anniversary of the Effective Date (the “Eighteen Month Window”), subject to additional time, on a country by country basis, as may be necessitated by
appropriate regulatory approvals in such country, where required to comply with Section 4.8(b), which shall be diligently undertaken by RITA, provided further, in each country where RITA desires that the Eighteen Month window be subject to
the foregoing adjustment and where any 

  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
regulatory approval is required in such country in connection with the foregoing, RITA will initiate regulatory efforts, including making any required
submission to the appropriate Regulatory Authority in such country, necessary to comply with RITA’s obligations under this Section 4.8(b) within six (6) months after the Effective Date, and will use its commercially reasonable efforts to
conclude the appropriate change(s) to the Existing Products of RITA and its Affiliates expeditiously and within eighteen (18) months after the Effective Date. 
  

4.9 Additional Covenant by BSC. In consideration for the licenses granted under this Agreement, the foregoing releases and
covenants not to sue under this Section 4, and so as not to induce or contribute to infringement of the RITA Temperature Sensor Claims, effective from the Effective Date until the expiration of the last-to-expire of the Claims within the RITA
Temperature Sensor Claims, BSC, for itself and for its Affiliates, hereby covenants and agrees not to knowingly promote through customer marketing efforts, either directly or through BSC’s or its Affiliates’ agents or distributors, the use
of temperature, nor to display temperature, in regard to the use of BSC’s (or its Affiliates’) Products made, have made, used, practiced, imported, offered for sale, sold or otherwise disposed of or made available for use in the Field
after the Effective Date. The Parties acknowledge that as of the Effective Date, Existing Products of BSC or its Affiliates do not display the use of temperature. 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 5. RESERVATIONS OF RIGHTS; PATENT PROSECUTION, MAINTENANCE AND ENFORCEMENT; ACKNOWLEDGEMENTS. 
  
 5.1 Reservation of Rights by RITA. Each of BSC, RTC,
Scimed, Nebraska and Kansas hereby acknowledges and agrees that RITA is and shall remain the owner of all rights, title and interests in and to the RITA Patent Portfolio and the RITA Infusion Claims, and that no Party shall acquire any rights
whatsoever in or to the RITA Patent Portfolio or the RITA Infusion Claims except as expressly provided in this Agreement. Further, no Party (other than RITA) shall utilize or practice under the RITA Patent Portfolio or the RITA Infusion Claims for
any purpose whatsoever, except as expressly authorized herein. RITA reserves all rights and licenses to the RITA Patent Portfolio and the RITA Infusion Claims not expressly granted to any Party hereunder. 
  
 5.2 Reservation of Rights by Nebraska and RTC. RITA
hereby acknowledges and agrees that Nebraska and RTC are and shall remain, respectively, the owner and exclusive sublicensee, of all rights, title and interests in and to the LeVeen Patent Portfolio, and RITA shall not acquire any rights whatsoever
in or to the LeVeen Patent Portfolio except as expressly provided in this Agreement. Further, RITA shall not utilize the LeVeen Patent Portfolio for any purpose whatsoever, except as expressly authorized herein. Nebraska and RTC reserve all rights
and licenses to the LeVeen Patent Portfolio not expressly granted to RITA hereunder. 
  
 5.3 Reservation of Rights by RTC. RITA hereby acknowledges and agrees that RTC is and shall remain the owner of all rights, title and interests in and to the RTC 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
RF Ablation Patent Portfolio, and RITA shall not acquire any rights whatsoever in or to the RTC RF Ablation Patent Portfolio except as expressly provided in
this Agreement. Further, RITA shall not utilize the RTC RF Ablation Patent Portfolio for any purpose whatsoever, except as expressly authorized herein. RTC reserves all rights and licenses to the RTC RF Ablation Patent Portfolio not expressly
granted to RITA hereunder. 
  
 5.4 Reservation of
Rights by Kansas and BSC. RITA hereby acknowledges and agrees that Kansas and BSC are and shall remain, respectively, the owner and exclusive licensee (subject to certain field of use limitations), of all rights, title and interests in and
to the Malone Patent Portfolio, and RITA shall not acquire any rights whatsoever in or to the Malone Patent Portfolio except as expressly provided in this Agreement. Further, RITA shall not utilize the Malone Patent Portfolio for any purpose
whatsoever, except as expressly authorized herein. Kansas and BSC reserve all rights and licenses to the Malone Patent Portfolio not expressly granted to RITA hereunder. 
  
 5.5 Reservation of Rights by Scimed. RITA hereby acknowledges and agrees that Scimed is and shall
remain the owner of all rights, title and interests in and to the LaFontaine Patent Portfolio, and RITA shall not acquire any rights whatsoever in or to any of the LaFontaine Patent Portfolio except as expressly provided in this Agreement. Further,
RITA shall not utilize any of the LaFontaine Patent Portfolio for any purpose whatsoever, except as expressly authorized herein. Scimed reserves all rights and licenses to the LaFontaine Patent Portfolio not expressly granted to RITA hereunder.

  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 5.6 Patent Prosecution, Maintenance and Enforcement. Subject to the terms and
conditions of this Agreement, each Party reserves the right, in such Party’s sole discretion, to prepare, file, prosecute, maintain and enforce in the Licensed Territories patents and patent applications with respect to such Party’s own
Patent Portfolio. 
  
 5.7 No Challenge Covenant by
RITA. Except in connection with patent interference proceedings originating in the United States Patent and Trademark Office with respect to patents or patent applications within the subject Patent Portfolio, RITA covenants and agrees that
RITA shall not, and shall cause its Affiliates not to, directly or indirectly, challenge or assist any other Person to challenge, the validity or enforceability of the patents or patent applications within the LeVeen, Malone, or RTC RF Ablation
Patent Portfolios that are subject to the licenses or covenants of this Agreement; provided that RITA (and its Affiliates) may challenge, or assist any other Person to challenge, the validity or enforceability of any patent asserted against
RITA (or its Affiliates) in an infringement action brought by another Party against RITA (or its Affiliates). 
  
 5.8 No Challenge Covenant by BSC. Except in connection with patent interference proceedings originating in the United States Patent
and Trademark Office with respect to patents or patent applications within the subject Patent Portfolio, BSC covenants and agrees that it shall not, and shall cause its Affiliates not to, directly or indirectly, challenge or assist any other Person
to challenge, the validity or enforceability of the patents or patent applications within the RITA Patent Portfolios of RITA that are subject to the licenses or covenants of this Agreement; provided that BSC (and its Affiliates) may
challenge, or assist any other Person to challenge, the validity or 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
enforceability of any patent asserted against BSC (or its Affiliates) in an infringement action brought by RITA against BSC (or its Affiliates). 

 
 6. REPRESENTATIONS AND WARRANTIES 
  
 6.1 Representations and Warranties by RITA. RITA hereby
represents and warrants to each of the other Parties that: 
  
 (a) it owns or has the right to grant the licenses, rights and immunities from suit granted herein under the RITA Patent Portfolio and the RITA Infusion Claims; 
  
 (b) it has full power to enter into this Agreement, and that the individual executing this Agreement on its behalf is
fully empowered to bind it and duly authorized to enter into this Agreement; and 
  
 (c) as of the Effective Date it has not assigned or otherwise transferred or subrogated any interest in any of its claims that are the subject of this Agreement, whether voluntarily, involuntarily or by
operation of law, and that it is fully entitled to give a full and complete release of all claims and demands under the Actions in accordance with the terms of this Agreement. 
  
 6.2 Representations and Warranties by Nebraska. Nebraska hereby represents and warrants to RITA that:

  
 (a) it owns or has the right to grant the licenses,
rights and immunities from suit granted herein under the LeVeen Patent Portfolio; 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 (b) it has full power to enter into this Agreement, and that the individual executing this
Agreement on its behalf is fully empowered to bind it and duly authorized to enter into this Agreement; and 
  
 (c) as of the Effective Date it has not assigned or otherwise transferred or subrogated any interest in any of its claims that are the subject of
this Agreement, whether voluntarily, involuntarily or by operation of law, and that it is fully entitled to give a full and complete release of all claims and demands under the Actions in accordance with the terms of this Agreement. 
  
 6.3 Representations and Warranties by RTC. RTC hereby
represents and warrants to RITA that: 
  
 (a) it has the
right to grant the licenses, rights and immunities from suit granted herein under the LeVeen Patent Portfolio; 
  
 (b) it owns or has the right to grant the licenses, rights and immunities from suit granted herein under the RTC RF Ablation Patent Portfolio;

  
 (c) it has full power to enter into this Agreement, and
that the individual executing this Agreement on its behalf is fully empowered to bind it and duly authorized to enter into this Agreement; and 
  
 (d) as of the Effective Date it has not assigned or otherwise transferred or subrogated any interest in any of its claims that are the subject of
this Agreement, whether voluntarily, involuntarily or by operation of law, and that it is fully entitled to 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
give a full and complete release of all claims and demands under the Actions in accordance with the terms of this Agreement. 
  
 6.4 Representations and Warranties by Kansas. Kansas
hereby represents and warrants to RITA that: 
  
 (a) it
owns or has the right to grant the licenses, rights and immunities from suit granted herein under the Malone Patent Portfolio; 
  
 (b) it has full power to enter into this Agreement, and that the individual executing this Agreement on its behalf is fully empowered to bind it
and duly authorized to enter into this Agreement; and 
  
 (c)
as of the Effective Date it has not assigned or otherwise transferred or subrogated any interest in any of its claims that are the subject of this Agreement, whether voluntarily, involuntarily or by operation of law, and that it is fully
entitled to give a full and complete release of all claims and demands under the Actions in accordance with the terms of this Agreement. 
  
 6.5 Representations and Warranties by BSC. BSC hereby represents and warrants to RITA that: 
  
 (a) it has the right to grant the licenses, rights and immunities
from suit granted herein under the Malone Patent Portfolio; 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 (b) it has full power to enter into this Agreement, and that the individual executing this
Agreement on its behalf is fully empowered to bind it and duly authorized to enter into this Agreement; and 
  
 (c) as of the Effective Date it has not assigned or otherwise transferred or subrogated any interest in any of its claims that are the subject of
this Agreement, whether voluntarily, involuntarily or by operation of law, and that it is fully entitled to give a full and complete release of all claims and demands under the Actions in accordance with the terms of this Agreement. 
  
 6.6 Representations and Warranties by Scimed. Scimed
hereby represents and warrants to RITA that: 
  
 (a) it
owns or has the right to grant the licenses, rights and immunities from suit granted herein under the LaFontaine Patent Portfolio; 
  
 (b) it has full power to enter into this Agreement, and that the individual executing this Agreement on its behalf is fully empowered to bind it
and duly authorized to enter into this Agreement; and 
  
 (c)
as of the Effective Date it has not assigned or otherwise transferred or subrogated any interest in any of its claims that are the subject of this Agreement, whether voluntarily, involuntarily or by operation of law, and that it is fully
entitled to give a full and complete release of all claims and demands under the Actions in accordance with the terms of this Agreement. 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 6.7 Disclaimer. Nothing in this Agreement nor in the grants of licenses hereunder
shall be construed as: 
  
 (a) a warranty or
representation by any Party as to the validity or scope of any patent within such Party’s subject Patent Portfolio; 
  
 (b) a warranty or representation by any Party that anything made, have made, used, imported, offered for sale, sold or otherwise disposed of under
or pursuant to this Agreement, or any other conduct, is or will be free from infringement of patents, intellectual property or other rights of any Third Person; 
  

(c) a requirement that any Party shall file any patent application, secure any patent or maintain any patent in force; 
  
 (d) an obligation to bring or prosecute any action or suit against any
Third Person for infringement of the patents within such Party’s subject Patent Portfolio or otherwise; 
  
 (e) an obligation to furnish any manufacturing or technological information; 
  
 (f) conferring the right to use in advertising, publicity or otherwise any trademark, service mark or trade name of
any Party; 
  
 (g) a warranty, representation or guaranty
by any Party with respect to the performance or failure of performance of any Product or Method by reason of its utilization or embodiment of any invention covered by a Claim of any of the patents 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
within such Party’s subject Patent Portfolio or otherwise, including, without limitation, that any Product or Method will not result in safety or health
hazards to purchasers, users, patients or workers, and such Party does not warrant, represent or guarantee against any health or safety hazards; or 
  
 (h) except as expressly provided herein, granting by implication, estoppel or otherwise, any licenses or rights under patents of a Party (including
any New Patents), or with respect to which such Party may have any rights, other than the patents within such Party’s subject Patent Portfolio as provided herein. 
  
 7. SUCCESSORS AND ASSIGNS 
  
 7.1 Successors and Assigns. This Agreement includes licenses of intellectual property for the purposes of § 365(n) of the U.S.
Bankruptcy Code. This Agreement shall bind and inure to the benefit of each of the Original Parties and their respective permitted successors and permitted assigns, and their respective Affiliates, and each of them. Affiliates of each Original Party
and of its respective permitted successors and permitted assigns are intended third party beneficiaries of this Agreement to the extent expressly provided herein. 
  
 7.2 Assignability. This Agreement, and the respective rights and obligations of the Original Parties
under this Agreement, shall be freely assignable or transferable, by merger, operation of law or in any other manner, by each of the Original Parties, only if assigned or transferred in whole, as part of an assignment or transfer of such Original
Party’s entire business or operations, or entire interests in the Field, provided that such 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
assigning or transferring Original Party shall retain no rights under this Agreement and the assignee or transferee of such Original Party assumes in writing
the obligations of such Original Party under this Agreement. Notwithstanding anything else in this Section 7.2, BSC and its Affiliates, and RITA and its Affiliates, acknowledge and agree that, with regard to the assignment or transfer of this
Agreement and their respective rights and obligations under this Agreement as a whole, this Agreement and such rights and obligations may only be so transferred by BSC and its Affiliates or by RITA and its Affiliates if and to the extent that each
of BSC and its Affiliates or each of RITA and its Affiliates assigns or transfers all of their respective rights and obligations hereunder concurrently and collectively to the same assignee or transferee, as applicable. 
  
 7.3 Partial Assignments by Sub-Field. In addition to,
and without limiting the rights and obligations of the Parties under Section 7.2, this Agreement, and any rights and licenses hereunder, may be assigned or transferred, by merger, operation of law or in any other manner, to any Person, in part, by
BSC and its Affiliates or by RITA and its Affiliates (the “Assigning Party”) within and as pertaining to any Sub-Field, only if transferred or assigned as part of an assignment or transfer of such Assigning Party’s entire
business, operations and interests in such Sub-Field; provided that (i) such Assigning Party shall retain no rights under this Agreement with respect to such Sub-Field and the assignee or transferee of such Assigning Party assumes in writing
the obligations of the Assigning Party under this Agreement with respect to the Sub-Field rights so assigned or transferred, and (ii) for any assignment or transfer of this Agreement with respect to a Sub-Field hereunder by either BSC and its
Affiliates or by RITA and its 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
Affiliates, all of BSC and its Affiliates or all of RITA and its Affiliates, as applicable, shall collectively be deemed to be the “Assigning
Party” hereunder and the restrictions set forth in (i) above shall apply equally to all of BSC and its Affiliates or to all of RITA and its Affiliates, as applicable. Notwithstanding any other provision of this Agreement, such Sub-Field
assignee or transferee shall have no obligations to any other Party outside the scope of the assigned or transferred Sub-Field, and the other Parties shall have no obligations to such assignee or transferee outside the scope of the assigned or
transferred Sub-Field. 
  
 7.4 Conditions on
Assignment. The Parties agree that, in the event that any Original Party or Assigning Party makes a permitted assignment or permitted transfer of its rights or licenses under this Agreement within the Field, or any Sub-Field, as applicable,
pursuant to the terms and conditions of Sections 7.2 or 7.3, the benefit of (i) all applicable licenses granted to such assigning or transferring Original Party or Assigning Party under Section 2, and (ii) all applicable releases and covenants not
to sue in favor of such assigning or transferring Original Party or Assigning Party under Sections 4.1, 4.2, 4.3, 4.5, 4.6, and/or 4.7 (as applicable), shall extend to such Original Party’s or Assigning Party’s permitted assignee or
permitted transferee (for purposes of this Section and Sections 7.5 and 7.6, an “Assignee”), solely to the extent of the activities of such Assignee in the Field or applicable Sub-Field including, without limitation, any Products of
the Original Party or Assigning Party, as applicable, that are within the Field or applicable Sub-Field and in existence at the time of the applicable assignment or transfer and any successor Products based upon and substantially utilizing the
functional 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
design of such Products (collectively, the “Assigned Products”); provided, however, that such licenses, releases and covenants not to sue
shall not extend to any Products of such Assignee as of the date of such permitted assignment or permitted transfer (“Assignee Existing Products”), or to any subsequent Products of such Assignee that are substantially similar to the
Assignee Existing Products in material aspects other than Assigned Products. Notwithstanding the foregoing, the Parties further agree that no such Assignee shall retain or be entitled to rely upon the benefit of the releases and covenants not to sue
set forth in Sections 4.1, 4.2, 4.3, 4.5, 4.6, and/or 4.7 (as applicable) if such Assignee initiates any infringement action within the Field, or Sub-Field as applicable, against any Original Party or Assigning Party (or any Affiliate or Assignee
thereof) having any rights pursuant to this Agreement. Subject to the foregoing, it is understood that the releases and covenants not to sue set forth in Sections 4.1, 4.2, 4.3, 4.5, 4.6, and 4.7 shall apply only to the Original Parties and the RITA
Releasees and BSC Releasees as expressly described in such Sections, and to Assignees of the Original Parties and Assigning Parties as expressly described in this Section 7.4, and do not relieve any other Person from any liability. 
  
 7.5 No Other Assignments. Subject only to the provisions
of Section 7.2 and Section 7.3, no Party, nor any of their respective permitted successors or permitted assigns, except as expressly set forth herein, may assign or otherwise transfer any part of its rights or licenses hereunder, nor delegate any
part of its duties hereunder, whether by merger, operation of law or in any other manner, without the written consent of each of the other Parties, provided however, that notwithstanding the foregoing, each of the 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
Original Parties may assign or transfer, by merger, operation of law or in any other manner, its rights and licenses and delegate its duties under this
Agreement, in whole or in part, to any of its Affiliates controlled by such Original Party without the prior written consent of the other Parties, so long as such Affiliate assumes in writing the obligations of such Original Party under this
Agreement. Original Parties and subsequent Assignees shall receive written notice from the Assigning Party within 30 days of any assignment, transfer or delegation undertaken in accordance with Section 7. Any purported assignment, transfer or
delegation not strictly in compliance with the terms and conditions of this Section 7 shall be void and of no effect. 
  
 7.6 Effect of Assignment. Except as otherwise provided below in this Section 7.6, any permitted assignment, transfer or delegation of
this Agreement, or any rights, licenses or duties hereunder, by any Party in accordance with the terms of this Section 7 shall not relieve or release such Party from any of its duties or obligations under this Agreement. However, with respect
to any obligation to pay royalties to RITA pursuant to Section 3.3, the assigning or transferring Party(ies) shall be relieved and released from any such obligations incurred by the Assignee after the assignment or transfer, provided that such
Assignee assumes in writing the obligations of such Party under this Agreement. Each and every permitted successor and permitted assign to the interests of any Party to this Agreement shall hold such interests subject to the terms, conditions and
provisions of this Agreement. Each Party to this Agreement shall require any subsequent transferee or owner of an patent rights included within its subject Patent 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
Portfolio to take such patent rights subject to the terms, conditions and provisions of this Agreement. 
  
 8. DISMISSAL WITH PREJUDICE 
  
 Within 20 days after the Effective Date, each Party shall respectively dismiss with
prejudice all causes of action, counts, claims for relief and allegations asserted against any other Party in the Actions, by filing an appropriate Stipulation of Dismissal in the form attached hereto as Exhibit G, with appropriate
insertions; provided, however, that with respect to the European Appeal and Opposition, RTC will instead withdraw its appeal. 
  
 9. TERM 
  
 Each respective license grant set forth in Section 2 shall commence as of the Effective Date and continue until the expiration of the last-to-expire of all of the Claims of the respective subject Patent Portfolio
licensed therein. Except as otherwise specifically provided with respect to particular covenants or provisions, this Agreement shall commence as of the Effective Date and continue in perpetuity. 
  
 10. DISCLOSURE 
  
 Each Party agrees that it shall not issue any press statement relating to or referring to this Agreement, the Actions or the activities
contemplated by this Agreement, prior to the execution of this Agreement by the Original Parties. In the event that BSC (and its Affiliates) or RITA (and its Affiliates) issues any press statement thereafter, the first such 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
statement issued by such Party shall be in the approved form attached as Exhibit H-1 for BSC (and its Affiliates) and Exhibit H-2 for RITA (and
its Affiliates). Each of Kansas and Nebraska may, in their sole discretion, issue press statements relating to or referring to this Agreement, the Actions or the activities contemplated by this Agreement subject to the prior written consent of RITA
and BSC such consent not to be unreasonably withheld. Subject to Section 11 and without limiting the foregoing, each Party further undertakes and agrees that any and all future statements made by such Party, or its respective Affiliates, to the
public, the media or to business associates, shall be entirely consistent with the press statement set forth in Exhibit H. 
  
 11. NONDISCLOSURE AND LIMITED USE 
  
 Except as otherwise provided in Section 10 above, the Parties agree that the specific terms and conditions of this Agreement and all information and materials exchanged
between the Parties pursuant to this Agreement are confidential and will be treated with the same care as other confidential information held by the Parties, and in any event no less than a reasonable degree of care, and not used for any purpose
other than to carry out the activities contemplated by this Agreement. Nevertheless, all Parties acknowledge that any Party may disclose the specific terms and conditions of this Agreement to attorneys, financial advisors, insurance carriers and
similar professionals working with such Party, including outside insurance counsel, under binding obligations of confidentiality, and as required to comply with binding orders of governmental entities that have jurisdiction over such Party, provided
that, in the event of such an order, the disclosing Party (i) whenever possible, shall give the other Parties written notice 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
sufficient to allow each other Party an opportunity to seek a protective order or other appropriate remedy; (ii) will disclose only such information as is
required by the governmental entity, and (iii) will use commercially reasonable efforts to obtain confidential treatment for the portions disclosed and to enforce such confidential treatment terms. Furthermore, nothing in this Agreement shall
prevent any Party from (a) disclosing information required to be disclosed by federal or state securities laws, or (b) filing a copy of this Agreement with the United States Patent and Trademark Office in accordance with 35 U.S.C. 135(c), provided
that such Party filing the same shall request that the filed copy be kept separate from the file of the interference and made available only to government agencies on written request, or to any Person on a showing of good cause as contemplated in 35
U.S.C. 135(c). This confidentially provision shall in all other respects continue to be in force for all Parties even if a disclosure of the Agreement’s terms is required. 
  
 12. DISPUTE RESOLUTION 
  
 12.1 Mediation. If a dispute arises out of, relates to or concerns the Parties’ licenses, rights or obligations under this
Agreement, the Parties will use good faith efforts, including if agreeable to the Parties the use of a third party mediator, to resolve the dispute in a timely and mutually acceptable fashion without recourse to judicial remedies. Nothing contained
herein shall prohibit a Party from resorting to the remedies provided for in Sections 12.2 and 12.3 in the event disputes are not resolved in a timely manner or to the satisfaction of all Parties. Each Party shall be responsible for its costs

  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
and expenses incurred as a result of any mediation. The Parties participating in the mediation shall share equally in the costs and expenses incurred by the
mediator. 
  
 12.2 Infringement Matters.
Without limiting the provisions of Section 12.1, in the event that any Party (the “Claimant”) makes any allegation or claim of infringement of a Claim in the Field against any other Party, the Claimant shall provide written
notification of such allegation or claim to the other Party at least ninety (90) days prior to filing any complaint relating thereto. For a period of ninety (90) days after the receipt of such written notice by the other Party, the parties agree to
use good faith efforts to resolve such allegation or claim in accordance with the provisions of Section 12.1 without resort to judicial remedies. If such allegation or claim is not thereby resolved, after complying with the foregoing requirements,
the Claimant may file a complaint only in the United States District Court for the Northern District of California. Each Party hereby consents to the exclusive jurisdiction of the said District Court in regard to any such allegation or claim.

  
 12.3 Arbitration. Any claims or disputes
arising out of, relating to or otherwise concerning the Parties’ obligations under this Agreement which are not resolved in accordance with Section 12.1 shall be submitted to binding arbitration in accordance with the terms and conditions for
arbitration set forth in Exhibit I; provided, however, that any claims or disputes arising under Title 35, United States Code, shall not be subject to such arbitration and shall be resolved pursuant to Section 12.2 above. Such
arbitration shall be conducted in San Francisco, California. 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 13. GENERAL PROVISIONS 
  

13.1 Choice of Law. This Agreement shall be interpreted, enforced and governed under the laws of the State of California, except
that its conflicts of law rules shall not apply. 
  
 13.2
Interpretation. This Agreement shall be given a fair and reasonable construction in accordance with the intent of the Parties and without regard to which Party may have drafted it. Section and subsection headings in this Agreement
are included for convenience of reference only and shall not constitute a part of this Agreement for any other purpose or be given any substantive effect. 
  
 13.3 Severability. If any provision of this Agreement is declared or found to be illegal, unenforceable or void, then all Parties
shall be relieved of all obligations arising under such provision, but only to the extent that such provision is illegal, unenforceable or void. Further, this Agreement shall be deemed amended by modifying such provision to the extent necessary to
make it legal and enforceable while preserving its intent or, if that is not possible, by substituting therefor another provision that is legal and enforceable and achieves the same intended objective. The remainder of this Agreement shall not be
affected by such illegal, unenforceable or void provision and each provision not so affected shall be enforced to the full extent permitted by law. 
  
 13.4 Modification and Waiver. This Agreement may be modified only by an instrument in writing signed by all of the Parties. No waiver
of the enforcement of any 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
provision of this Agreement shall be effective unless in writing signed by the waiving Party nor shall it be deemed a continuing waiver. 
  
 13.5 Further Acts. Each Party shall do, or cause to be
done, all such further acts, and shall execute, acknowledge and deliver, or cause to be executed, acknowledged and delivered, any and all such further documentation as any other Party reasonably requires to carry out the purposes of this Agreement.

  
 13.6 Performance by Affiliates. To the
extent that any term or provision of this Agreement contemplates, permits or requires performance by any Affiliate of a Party, such Party shall cause such Affiliate to perform each and every obligation of such Party under this Agreement in
accordance with the terms and conditions hereof. 
  
 13.7
Acknowledgment. Each Party acknowledges that it knows and understands the contents of this Agreement and has been represented by counsel of its choice in connection with this Agreement, and has executed this Agreement voluntarily.

  
 13.8 Counterparts. This Agreement may be
executed in counterparts and by facsimile transmission of such counterparts, all of which taken together shall constitute one agreement binding upon the Parties. This Agreement shall become effective, as of the Effective Date, upon the execution of
a counterpart hereof by each of the Parties hereto. 
  
 13.9
Differences in Fact or Law. Each Party agrees that if the facts or law with respect to this Agreement are found hereafter to be different from the facts or law 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 
now believed by it to be true, it expressly assumes the risk of such possible difference of fact or law, and it agrees that this Agreement shall remain in
full force and effect notwithstanding such difference in fact or law. 
  
 13.10 Taxes. In the event that any sales or use taxes or other charges, if any, may be imposed by any government taxing authority on the amounts paid by any Party to any other Party under this Agreement, all such taxes
and charges shall be borne and paid by the Party receiving the underlying payment. Where any Party is required to pay taxes or charges for the account of another Party, such Party may withhold such taxes or charges from the amounts paid to the other
Party under this Agreement and shall deliver to the other Party true copies of the receipts and returns covering all such payments. 
  
 13.11 Entire Agreement. This Agreement constitutes the entire agreement of the Parties with respect to its subject matter, and
supersedes, merges and replaces all prior negotiations, offers, representations, warranties, assurances and agreements of any kind, written or oral. The recitals set forth in this Agreement and the exhibits attached hereto are hereby incorporated
into this Agreement and made a part hereof. 
  
 14. DISCLAIMER OF CONSEQUENTIAL
DAMAGES 
  
 IN NO EVENT SHALL ANY PARTY OR ITS RESPECTIVE AFFILIATES BE
LIABLE OR RESPONSIBLE FOR INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS) ARISING FROM OR RELATING TO ANY BREACH OF OR DEFAULT UNDER THIS AGREEMENT. 
  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

 IN WITNESS WHEREOF, the Parties have executed this Agreement effective as of the Effective Date. 
  

	Radio Therapeutics Corporation	 	 	 	Rita Medical Systems, Inc.
					
	By:	 	 /s/ Larry Knopf

	 	 	 	By:	 	 /s/ Barry Cheskin

					
	 Name:
	 	 Larry Knopf
	 	 	 	 Name:
	 	 Barry Cheskin

					
	 Title:
	 	 Vice President – Legal and Secretary
	 	 	 	 Title:
	 	 President and Chief Executive Officer

				
	Boston Scientific Corporation	 	 	 	 	 	 
					
	 By:
	 	 /s/ Stephen F. Moreci

	 	 	 	 	 	 
					
	 Name:
	 	 Stephen F. Moreci
	 	 	 	 	 	 
					
	 Title:
	 	Senior Vice President and Group President, Endosurgery	 	 	 	 	 	 

  

 ***Material has been omitted pursuant to a request for confidential treatment and such material has been filed
separately with the SEC. 

	Scimed Life Systems, Inc.
		
	 By:
	 	 /s/ Larry Knopf

		
	 Name:
	 	 Larry Knopf

		
	 Title:
	 	 Assistant Secretary

	
	Board of Regents of the University of Nebraska
		
	 By:
	 	 /s/ Donald S. Leuenberger

		
	 Name:
	 	 Donald S. Leuenberger

		
	 Title:
	 	 Vice Chancellor for Business and Finance

	
	UneMed Corporation
		
	 By:
	 	 /s/ Richard A. Spellman

		
	 Name:
	 	 Richard A. Spellman

		
	 Title:
	 	 Chairman of the Board

	 University of Kansas d/b/a University of
 Kansas Medical Center

		
	 By:
	 	 /s/ Donald F. Hagen, MD

		
	 Name:
	 	 Donald F. Hagen, MD

		
	 Title:
	 	 Executive Vice Chancellor

	
	 University of Kansas Medical Center
 Research Institute, Inc.

		
	 By:
	 	 /s/ Thomas Noffsinger Ph.D.

		
	 Name:
	 	 Thomas Noffsinger Ph.D.

		
	 Title:
	 	 Executive Director

 Exhibit A 
  
 LaFontaine Patent Portfolio 
  
 U.S. Patent No. 5,584,872 
  
 U.S. Patent No. 5,676,693 
  
 U.S. Patent No. 5,902,328 
  
 U.S. Patent No. 6,068,653 
  
 U.S. Patent No. 6,168,594 

 Exhibit B 
  
 LeVeen Patent Portfolio 
  
 U.S. Patent No. 5,827,276 
  
 U.S. Patent No. 5,855,576 
  
 U.S. Patent No. 5,868,740 
  
 U.S. Patent No. 6,454,765 
  
 U.S. Patent No. 6,468,273 

 Exhibit C 
  
 Malone Patent Portfolio 
  
 U.S. Patent No. RE. 35,330 

 Exhibit D 
  
 RITA Patent Portfolio 
  

	 U.S. Patent No. 5,458,597
	  	 U.S. Patent No. 5,913,855

		
	 U.S. Patent No. 5,472,441
	  	 U.S. Patent No. 5,925,042

		
	 U.S. Patent No. 5,486,161
	  	 U.S. Patent No. 5,928,229

		
	 U.S. Patent No. 5,507,743
	  	 U.S. Patent No. 5,935,123

		
	 U.S. Patent No. 5,536,267
	  	 U.S. Patent No. 5,951,547

		
	 U.S. Patent No. 5,599,345
	  	 U.S. Patent No. 5,980,517

		
	 U.S. Patent No. 5,599,346
	  	 U.S. Patent No. 6,053,937

		
	 U.S. Patent No. 5,672,173
	  	 U.S. Patent No. 6,059,780

		
	 U.S. Patent No. 5,672,174
	  	 U.S. Patent No. 6,071,280

		
	 U.S. Patent No. 5,683,384
	  	 U.S. Patent No. 6,080,150

		
	 U.S. Patent No. 5,728,143
	  	 U.S. Patent No. 6,090,105

		
	 U.S. Patent No. 5,735, 847
	  	 U.S. Patent No. 6,132,425

		
	 U.S. Patent No. 5,741,225
	  	 U.S. Patent No. 6,235,023

		
	 U.S. Patent No. 5,782,827
	  	 U.S. Patent No. 6,330,478

		
	 U.S. Patent No. 5,800,484
	  	 U.S. Patent No. 6,471,698

		
	 U.S. Patent No. 5,810,804
	  	 U.S. Patent No. 6,500,175

		
	 U.S. Patent No. 5,863,290
	  	 

 Exhibit E 
  
 RTC RF Ablation Patent Portfolio 
  
 U.S. Patent No. 5,709,224 
  
 U.S. Patent No. 5,817,092 
  
 U.S. Patent No. 5,954,717 
  
 U.S. Patent No. 6,050,992 
  
 U.S. Patent No. 6,077,261 
  
 U.S. Patent No. 6,080,149 
  
 U.S. Patent No. 6,212,433 
  
 U.S. Patent No. 6,270,495 
  
 U.S. Patent No. 6,337,998 
  
 U.S. Patent No. 6,358,246 
  
 U.S. Patent No. 6,379,353 
  
 U.S. Patent No. 6,470,218 
  
 U.S. Patent No. 6,471,695 

 Exhibit F 
  
 Payment Wiring Instructions 
  
 University of Kansas 
  
 [***] 
  
 University of Nebraska 
  
 [***]

 Exhibit G 
  
 Form of Stipulation of Dismissal 

 Exhibit H 
  
 Approved Press Statements 
  
 H-1 – Press Statement of BSC (and its Affiliates) 
  
 Boston Scientific Announces Settlement of Patent Disputes with Rita Medical Systems 
  
 Boston Scientific Corporation (NYSE:BSX) today announced that it has settled all pending
patent disputes with Rita Medical Systems, Inc (Nasdaq:RITA). The patent disputes involved technologies used for the reduction of tumors using radiofrequency energy. The parties have agreed to cross-license certain intellectual property and Rita
Medical Systems will pay a one-time royalty fee to both the University of Kansas and the University of Nebraska, the licensors of certain patents to Boston Scientific. In addition, Boston Scientific acquired a royalty-bearing license to Rita Medical
Systems’ infusion technology for future products. 
  
 H-2 – Press
Statement of RITA (and its Affiliates)  
  
 RITA Medical Systems And
Boston Scientific Settle Patent Dispute 
  
 MOUNTAIN VIEW, CA (April XX, 2003) . .
.. RITA Medical Systems, Inc. (Nasdaq:RITA) announced today that it had signed a definitive agreement with Boston Scientific Corporation (NYSE:BSX) and its affiliates to settle all outstanding patent disputes involving the two companies. The
agreement includes a series of licenses and sub-licenses. Not included in the licenses is RITA’s proprietary temperature control technology. 
  
 Under the terms of the agreement, RITA will make a one time payment of $2.65 million to the Universities of Kansas and Nebraska, who are the licensors of several of the
disputed patents. In addition, RITA agreed to license to Boston Scientific, on a royalty-bearing basis, its infusion technology for future products. Boston Scientific will not 

 market or sell products utilizing the infusion license until 18 months after the date of the agreement. 
  
 “It is with great pleasure that we put the expense, distraction and uncertainty of our
patent dispute with Boston Scientific behind us,” said RITA Medical Systems President and Chief Executive Officer Barry Cheskin. “We look forward to focusing our energies and resources instead on developing the large potential market for
radiofrequency ablation of tumors.” 
  
 Cheskin noted that the total legal
expenses associated with the dispute would otherwise have been expected to be around $4-5 million in 2003 alone. 
  

 2 

 Exhibit I 
  
 Arbitration 
  
 The Parties have entered into these terms and conditions for arbitration (the “Arbitration Terms”) to provide for arbitration of disputes as set forth in
the Agreement. The Parties intend and agree that any such arbitration(s) shall be in the nature of a judicial proceeding, except as provided herein, that the dispute shall be resolved by an arbitration panel composed of three arbitrators (the
“Arbitrators”) with technical expertise in patent law and technology licensing, to be selected as provided in these Arbitration Terms. The Parties recognize that there may be multiple disputes subject to these Arbitration Terms, and
to the extent that they arise at different times, there may be multiple, separate arbitrations. 
  

	 	1.	 	Location and Applicable Law. The arbitration, including the final hearing (the “Final Hearing,” as described in paragraph 9), shall be conducted in English
in San Francisco, California unless otherwise agreed in writing by the parties to such arbitration. The applicable law shall be the laws of the State of California, except that California’s conflicts of law rules shall not apply.

  

	 	2.	 	 Rules Applicable to the Arbitration. Except as otherwise provided in these Arbitration Terms, the arbitration shall be administered by the American
Arbitration Association (“AAA”) under its Commercial Arbitration Rules (the “Rules”) and such Rules are hereby incorporated into these Arbitration Terms. To the extent a specific provision of the Arbitration Terms
conflicts with a 

	 	 
provision of the Rules, the specific provision of these Arbitration Terms shall control. 

  

	 	3.	 	Notice. The demand setting forth notice of its intention to arbitrate or the written submission to arbitrate, as described in the Rules (the “Demand”), shall
be submitted by a Party seeking arbitration (the “Claimant”) simultaneously to both the AAA and the respondent(s) in the arbitration (the “Respondents”). The addresses of the Parties for purposes of delivering the
Demand are as follows: 

  
 Rita
Medical Systems, Inc. 
 967 North Shoreline Boulevard 
 Mountain View, California 94043 
 Attention: Barry Cheskin 
  
 RadioTherapeutics Corporation 
 One Boston Scientific Place 
 Natick, Massachusetts 01760 
 Attention: Scott Bluni, Esq. 
  
 Boston Scientific Corporation 
 One Boston Scientific Place 
 Natick, Massachusetts 01760 
 Attention: Scott Bluni, Esq. 
  
 Scimed Life Systems, Inc. 
 One Boston Scientific Place 
 Natick, Massachusetts 01760 
 Attention: Scott Bluni, Esq. 
  
 Board of Regents of the University of Nebraska 
 c/o UNMC Intellectual Property Office

 986099 Nebraska Medical Center 
 Omaha, Nebraska 68198-6099 
 Attention: Leonard Agneta, Esq. 
  
 UneMed Corporation 
 c/o UNMC Intellectual Property Office 
 986099 Nebraska Medical Center 
 Omaha, Nebraska 68198-6099 
 Attention: Leonard Agneta, Esq. 
  

 2 

 University of Kansas d/b/a University of Kansas Medical Center 
 1450 Jayhawk Boulevard 
 245 Strong Hall 
 Lawrence, Kansas 66045 
 Attention: James P. Pottorff, Esq. 
  
 University of Kansas Medical Center Research Institute, Inc. 
 3901 Rainbow Boulevard, 
 Mailstop 1039 
 Kansas City, Kansas 66160 
 Attention: Jane E. Rosenthal, Esq. 
  

	 	4.	 	 The Arbitrators. Any proposed Arbitrator must, prior to appointment as Arbitrator, certify that he/she has read these Arbitration Terms and agrees to be
bound by all of the provisions set forth herein, including, but not limited to, any time limitations set forth in these Arbitration Terms. Each of the Arbitrators shall have knowledge of patent law and patent licensing and (i) must not currently be,
or have been within the past five years, a shareholder of any Party or an Affiliate of any Party; (ii) must not have, or had at any time, a business relationship with a Party; (iii) must not currently be, or have been at any time, an employee or
director of a Party and (iv) must not represent, or have represented at any time, a Party; unless the other Parties waive each of these objections. Subject to the foregoing, the Arbitrators will be chosen by the Parties within thirty (30) calendar
days after submission of the Demand to the Respondent and the AAA. The arbitration panel shall be composed of three Arbitrators, one of whom shall be selected by RITA, one of whom shall be selected by the other Party (or Parties) to the dispute and
the third of whom shall be a neutral arbitrator selected by the other two so selected. If both or either of RITA and the other Party (or Parties) fails to select an arbitrator or arbitrators within such thirty (30) day period, or if 

  

 3 

	 	 
the two arbitrators fail to select a third neutral arbitrator within fourteen (14) calendar days after their appointment, then the Arbitrators will be chosen
pursuant to the procedures set forth in the Rules for the appointment from the National Panel of Commercial Arbitrators (the “Panel”) within thirty (30) calendar days of submission to the AAA by a Party of a request for appointment
of an arbitrator or arbitrators. If during the course of the arbitration, any of the Arbitrators initially selected in accordance with the foregoing procedures dies or becomes otherwise unavailable to serve as Arbitrator, a substitute Arbitrator
shall be chosen from the Panel pursuant to the procedures set forth in the Rules. 

  

	 	5.	 	Powers of the Arbitrators. The Arbitrators shall: (1) have the right to choose one or more advisors, including an expert on technology, technology licensing, legal counsel
(if none of the Arbitrators are a lawyer or judge) and/or an expert in any other area that the Arbitrators deem necessary to assist them in the arbitration; (2) have the power to order any discovery the Arbitrators deem necessary and to issue
sanctions, including costs, attorneys’ fees or monetary penalties, for failure to comply with such orders or for failure to comply with the rules set forth in these Arbitration Terms; and (3) have the right to make interim, interlocutory or
partial awards or take whatever other interim measures are necessary, including issuing injunctive relief and taking other measures for the preservation, protection, conservation or disposal of any property or things under the control of a Party.

  

 4 

	 	6.	 	Initial Scheduling Conference. Within ten (10) calendar days after submission of the Respondent’s response to the Demand as described in the Rules (the
“Answering Statement”) or if the Arbitrators have not been chosen by that date, within ten (10) calendar days after selection of the Arbitrators, the Arbitrators shall hold a conference, which may be conducted telephonically, at
which the Arbitrators shall (1) fix the timetable for submissions and discovery; (2) set the time and place for hearings; (3) determine any procedures to be followed in the arbitration that have not already been provided for in these Arbitration
Terms; and (4) discuss any other preliminary issues the Arbitrators or the Parties wish to raise. 

  

	 	7.	 	Discovery. Discovery in the arbitration shall consist of exchanges of documents and depositions and shall be completed within 120 calendar days after submission to Claimant
of the Answering Statement. Except as provided herein, the Parties shall be entitled to take all discovery, including third-party discovery, permitted under Rules 26, 27, 28, 29, 30, 34, 37 and 45 of the Federal Rules of Civil Procedure, and shall
have the same obligations as under the Federal Rules of Civil Procedure. The Arbitrators shall have the same powers with respect to discovery, including the power to order sanctions, as under the Federal Rules of Civil Procedure, including Rule 37
— except as specifically provided for below. 

  
 (a) Documents - In the exchanges of documents, each Party shall produce all documents, not privileged, that are relevant to the factual issues in the case, including all documents relevant to the matter(s) specified in the Demand,

  

 5 

 
Answering Statement, and counterclaim (“Counterclaim”), if any, and all documents that it intends to rely upon in the arbitration. Documents
not disclosed during discovery shall not be subject to use in subsequent submissions or hearings, except upon consent of the Parties or where the Arbitrators determine that such use is justified. 
  
 (b) Depositions - Each Party shall, at the request of the other
Party, produce for deposition up to six (6) employees possessing information relevant to the factual issues in the arbitration. Each Party will also be entitled to depose up to three (3) third-party witnesses and any expert witnesses designated to
testify at the hearing. In addition, during the thirty (30) calendar days prior to the Final Hearing, each Party shall have the right to depose any witness identified in the pre-hearing list of witnesses identified in paragraph 10 herein who was not
previously deposed by that Party during the discovery period. The Arbitrators may permit further depositions if the Arbitrators determine in their discretion that additional depositions are necessary. Depositions shall be no longer than one 8-hour
day, except that each Party may designate two persons whose depositions may be up to two 8-hour days long. 
  
 (c) Third Parties - The Parties agree that third-party discovery shall be permitted and conducted to the same extent as under the Federal Rules of
Civil Procedure. The Parties are required to use their best efforts to ensure that third-parties with information relevant to the factual issues in the arbitration, including any matter(s) specified in the Demand, Answering Statement and any 

  

 6 

 
Counterclaim, if any, provide the Arbitrators with any documents or testimony the Arbitrators may request. 
  
 (d) Sanctions - The Arbitrators shall be authorized to take one or
more of the following actions with respect to a Party that has either improperly refused to respond to a proper discovery request, responded to such request in an untimely fashion, or otherwise engaged in discovery abuse or serious violations of the
rules of the proceeding: (1) draw adverse interferences against the offending Party concerning facts in issue relating to such discovery ; (2) preclude the offending Party from presenting evidence concerning such facts; (3) award costs and/or
monetary penalties to the Party seeking the discovery, including attorneys’ fees; or (4) take any other actions authorized under the Federal Rules of Civil Procedure. 
  

	 	8.	 	Briefs, Witness Statements and Expert Reports. No brief or witness statement submitted during the course of the arbitration shall exceed twenty-five (25) pages in length,
except that thirty (30) calendar days after the conclusion of the hearing, each Party may submit to the other and to the Arbitrators a post-hearing brief no longer than 50 pages. Sixty (60) calendar days prior to the Final Hearing, the Parties shall
submit expert witness reports in the same format required by the Federal Rules of Civil Procedure for each expert witness the Party plans to call at the Final Hearing. 

  

 7 

	 	9.	 	The Final Hearing. The Final Hearing will be no longer than ten (10) business days, and shall be completed within a period of one month, unless the Arbitrators determine that
a longer hearing and/or completion period is necessary. 

  
 At the Final Hearing, each Party shall be entitled to make opening and closing statements and to conduct direct examination, cross-examination and re-direct examination of fact and expert witnesses. 
  
 Forty-five (45) calendar days before the hearing, each Party participating
in the arbitration will submit to each other and to the Arbitrators: (1) a list identifying all fact and expert witnesses that it intends to examine at the Final Hearing as part of its case-in-chief and; and (2) copies of all exhibits that the Party
intends to introduce at the hearing. All fact and expert witnesses disclosed in a Party’s list who have not previously been deposed by the other Party can be deposed prior to the Final Hearing. 
  

	 	10.	 	Award. The award shall consist of a writing setting forth the legal and factual bases of the Arbitrators’ decision and shall be rendered no more than one year after
service of the Demand. 

  

	 	11.	 	Damages. The Arbitrators shall have the power to award all actual damages suffered by an aggrieved Party. 

  

	 	12.	 	 Interest; Costs of Enforcement. The Arbitrators shall award to the prevailing Party on any claim, as determined by the Arbitrators, interest on any damages
incurred for breach or other violation of these Arbitration Terms from the date of 

  

 8 

	 	 
award until paid in full, at the prevailing statutory rate of interest under the laws of the State of California. Any costs, fees or taxes incident to
enforcing an award shall, to the maximum extent permitted by law, be charged against the Party resisting such enforcement. 

  

	 	13.	 	Confidentiality of Proceedings. The arbitration proceeding will be confidential and the Arbitrators will issue appropriate protective orders to safeguard each Parties’
confidential information. Except as required by law, no Party will disclose (or instruct the Arbitrators to disclose) to any non-participants in the arbitration the fact, conduct or outcome of the arbitration without the prior written consent of
each other Party to such arbitration. The existence of any dispute submitted to arbitration, and the award of the Arbitrators will be kept in confidence by the Parties and the Arbitrators, except as required in connection with the enforcement of
such award or as otherwise required by applicable law. Any Party who fails to observe the confidentiality restrictions in these Arbitration Terms shall be subject to the imposition of monetary sanctions by the Arbitrators. 

 

	 	14.	 	Entry of Judgment. Judgment upon the award rendered by the Arbitrators may be entered in any court having jurisdiction thereof. 

  

 9Form of Indemnification

 Exhibit 10.33 
  
 INDEMNIFICATION AGREEMENT 
  
 This Indemnification Agreement (the “Agreement”) is made as of
                , by and between RITA Medical Systems, Inc., a Delaware corporation (the “Company”), and
                                     (the
“Indemnitee”). 
  
 RECITALS

  
 The Company and Indemnitee recognize the increasing
difficulty in obtaining liability insurance for directors, officers and key employees, the significant increases in the cost of such insurance and the general reductions in the coverage of such insurance. The Company and Indemnitee further recognize
the substantial increase in corporate litigation in general, subjecting directors, officers and key employees to expensive litigation risks at the same time as the availability and coverage of liability insurance has been severely limited.
Indemnitee does not regard the current protection available as adequate under the present circumstances, and Indemnitee and agents of the Company may not be willing to continue to serve as agents of the Company without additional protection. The
Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, and to indemnify its directors, officers and key employees so as to provide them with the maximum protection permitted by law. 
  
 AGREEMENT 
  
 In consideration of the mutual promises made in this Agreement, and for other
good and valuable consideration, receipt of which is hereby acknowledged, the Company and Indemnitee hereby agree as follows: 
  
 1. Indemnification. 
  
 (a) Third Party Proceedings. The Company shall indemnify Indemnitee if Indemnitee is or was a party or is threatened to be made a party to
any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Company) by reason of the fact that Indemnitee is or was a director, officer,
employee or agent of the Company, or any subsidiary of the Company, by reason of any action or inaction on the part of Indemnitee while an officer or director or by reason of the fact that Indemnitee is or was serving at the request of the Company
as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement (if such settlement is
approved in advance by the Company, which approval shall not be unreasonably withheld) actually and reasonably incurred by Indemnitee in connection with such action, suit or proceeding if Indemnitee acted in good faith and in a manner Indemnitee
reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe Indemnitee’s conduct was unlawful. The termination of any action, suit
or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee 

 reasonably believed to be in or not opposed to the best interests of the Company, or, with respect to any criminal action
or proceeding, that Indemnitee had reasonable cause to believe that Indemnitee’s conduct was unlawful. 
  
 (b) Proceedings By or in the Right of the Company. The Company shall indemnify Indemnitee if Indemnitee was or is a party or is threatened
to be made a party to any threatened, pending or completed action or proceeding by or in the right of the Company or any subsidiary of the Company to procure a judgment in its favor by reason of the fact that Indemnitee is or was a director,
officer, employee or agent of the Company, or any subsidiary of the Company, by reason of any action or inaction on the part of Indemnitee while an officer or director or by reason of the fact that Indemnitee is or was serving at the request of the
Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees) and, to the fullest extent permitted by law, amounts paid in
settlement (if such settlement is approved in advance by the Company, which approval shall not be unreasonably withheld), in each case to the extent actually and reasonably incurred by Indemnitee in connection with the defense or settlement of such
action or suit if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company and its stockholders, except that no indemnification shall be made in respect of any claim,
issue or matter as to which Indemnitee shall have been finally adjudicated by court order or judgment to be liable to the Company in the performance of Indemnitee’s duty to the Company and its stockholders unless and only to the extent that the
court in which such action or proceeding is or was pending shall determine upon application that, in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnity for such expenses which such court shall deem
proper. 
  
 (c) Mandatory Payment of Expenses. To
the extent that Indemnitee has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in Section 1(a) or Section 1(b) or the defense of any claim, issue or matter therein, Indemnitee shall be indemnified
against expenses (including attorneys’ fees) actually and reasonably incurred by Indemnitee in connection therewith. 
  
 2. No Employment Rights. Nothing contained in this Agreement is intended to create in Indemnitee any right to continued employment.

  
 3. Expenses; Indemnification Procedure.

  
 (a) Advancement of Expenses. The Company shall
advance all expenses incurred by Indemnitee in connection with the investigation, defense, settlement or appeal of any civil or criminal action, suit or proceeding referred to in Section l(a) or Section 1(b) hereof (including amounts actually paid
in settlement of any such action, suit or proceeding). Indemnitee hereby undertakes to repay such amounts advanced only if, and to the extent that, it shall ultimately be determined that Indemnitee is not entitled to be indemnified by the Company as
authorized hereby. 
  
 (b) Notice/Cooperation by
Indemnitee. Indemnitee shall, as a condition precedent to his or her right to be indemnified under this Agreement, give the Company notice in 
  

 -2- 

 writing as soon as practicable of any claim made against Indemnitee for which indemnification will or could be sought
under this Agreement. Notice to the Company shall be directed to the Chief Executive Officer of the Company and shall be given in accordance with the provisions of Section 12(d) below. In addition, Indemnitee shall give the Company such information
and cooperation as it may reasonably require and as shall be within Indemnitee’s power. 
  
 (c) Procedure. Any indemnification and advances provided for in Section 1 and this Section 3 shall be made no later than twenty (20) days after receipt of the written request of Indemnitee. If a claim
under this Agreement, under any statute, or under any provision of the Company’s Certificate of Incorporation or Bylaws providing for indemnification, is not paid in full by the Company within twenty (20) days after a written request for
payment thereof has first been received by the Company, Indemnitee may, but need not, at any time thereafter bring an action against the Company to recover the unpaid amount of the claim and, subject to Section 11 of this Agreement, Indemnitee shall
also be entitled to be paid for the expenses (including attorneys’ fees) of bringing such action. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in connection with any action,
suit or proceeding in advance of its final disposition) that Indemnitee has not met the standards of conduct which make it permissible under applicable law for the Company to indemnify Indemnitee for the amount claimed, but the burden of proving
such defense shall be on the Company and Indemnitee shall be entitled to receive interim payments of expenses pursuant to Section 3(a) unless and until such defense may be finally adjudicated by court order or judgment from which no further right of
appeal exists. It is the parties’ intention that if the Company contests Indemnitee’s right to indemnification, the question of Indemnitee’s right to indemnification shall be for the court to decide, and neither the failure of the
Company (including its Board of Directors, any committee or subgroup of the Board of Directors, independent legal counsel, or its stockholders) to have made a determination that indemnification of Indemnitee is proper in the circumstances because
Indemnitee has met the applicable standard of conduct required by applicable law, nor an actual determination by the Company (including its Board of Directors, any committee or subgroup of the Board of Directors, independent legal counsel, or its
stockholders) that Indemnitee has not met such applicable standard of conduct, shall create a presumption that Indemnitee has or has not met the applicable standard of conduct. 
  
 (d) Notice to Insurers. If, at the time of the receipt of a notice of a claim pursuant to Section 3(b) hereof,
the Company has director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall
thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies. 
  
 (e) Selection of Counsel. In the event the Company shall be
obligated under Section 3(a) hereof to pay the expenses of any proceeding against Indemnitee, the Company, if appropriate, shall be entitled to assume the defense of such proceeding, with counsel approved by Indemnitee, upon the delivery to
Indemnitee of written notice of its election so to do. After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee under this Agreement for any
fees 
  

 -3- 

 of counsel subsequently incurred by Indemnitee with respect to the same proceeding, provided that (i) Indemnitee shall
have the right to employ counsel in any such proceeding at Indemnitee’s expense; and (ii) if (A) the employment of counsel by Indemnitee has been previously authorized by the Company, (B) Indemnitee shall have reasonably concluded that there
may be a conflict of interest between the Company and Indemnitee in the conduct of any such defense or (C) the Company shall not, in fact, have employed counsel to assume the defense of such proceeding, then the fees and expenses of
Indemnitee’s counsel shall be at the expense of the Company. 
  
 4. Additional Indemnification Rights; Nonexclusivity. 
  
 (a) Scope. Notwithstanding any other provision of this Agreement, the Company hereby agrees to indemnify the Indemnitee to the fullest extent permitted by law, notwithstanding that such indemnification
is not specifically authorized by the other provisions of this Agreement, the Company’s Certificate of Incorporation, the Company’s Bylaws or by statute. In the event of any change, after the date of this Agreement, in any applicable law,
statute, or rule which expands the right of a Delaware corporation to indemnify a member of its board of directors or an officer, such changes shall be deemed to be within the purview of Indemnitee’s rights and the Company’s obligations
under this Agreement. In the event of any change in any applicable law, statute or rule which narrows the right of a Delaware corporation to indemnify a member of its board of directors or an officer, such changes, to the extent not otherwise
required by such law, statute or rule to be applied to this Agreement shall have no effect on this Agreement or the parties’ rights and obligations hereunder. 
  
 (b) Nonexclusivity. The indemnification provided by this Agreement shall not be deemed exclusive of any rights
to which Indemnitee may be entitled under the Company’s Certificate of Incorporation, its Bylaws, any agreement, any vote of stockholders or disinterested members of the Company’s Board of Directors, the General Corporation Law of the
State of Delaware, or otherwise, both as to action in Indemnitee’s official capacity and as to action in another capacity while holding such office. The indemnification provided under this Agreement shall continue as to Indemnitee for any
action taken or not taken while serving in an indemnified capacity even though he or she may have ceased to serve in any such capacity at the time of any action, suit or other covered proceeding. 
  
 5. Partial Indemnification. If Indemnitee is entitled under any
provision of this Agreement to indemnification by the Company for some or a portion of the expenses, judgments, fines or penalties actually or reasonably incurred in the investigation, defense, appeal or settlement of any civil or criminal action,
suit or proceeding, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion of such expenses, judgments, fines or penalties to which Indemnitee is entitled. 
  
 6. Mutual Acknowledgment. Both the Company and Indemnitee
acknowledge that in certain instances, Federal law or public policy may override applicable state law and prohibit the Company from indemnifying its directors and officers under this Agreement or otherwise. For example, the Company and Indemnitee
acknowledge that the Securities and Exchange Commission (the “SEC”) has taken the position that indemnification is not permissible for liabilities arising under certain federal securities laws, and federal legislation prohibits

  

 -4- 

 indemnification for certain ERISA violations. Indemnitee understands and acknowledges that the Company has undertaken or
may be required in the future to undertake with the SEC to submit the question of indemnification to a court in certain circumstances for a determination of the Company’s right under public policy to indemnify Indemnitee. 
  
 7. Officer and Director Liability Insurance. The Company shall,
from time to time, make the good faith determination whether or not it is practicable for the Company to obtain and maintain a policy or policies of insurance with reputable insurance companies providing the officers and directors of the Company
with coverage for losses from wrongful acts, or to ensure the Company’s performance of its indemnification obligations under this Agreement. Among other considerations, the Company will weigh the costs of obtaining such insurance coverage
against the protection afforded by such coverage. In all policies of director and officer liability insurance, Indemnitee shall be named as an insured in such a manner as to provide Indemnitee the same rights and benefits as are accorded to the most
favorably insured of the Company’s directors, if Indemnitee is a director; or of the Company’s officers, if Indemnitee is not a director of the Company but is an officer; or of the Company’s key employees, if Indemnitee is not an
officer or director but is a key employee. Notwithstanding the foregoing, the Company shall have no obligation to obtain or maintain such insurance if the Company determines in good faith that such insurance is not reasonably available, if the
premium costs for such insurance are disproportionate to the amount of coverage provided, if the coverage provided by such insurance is limited by exclusions so as to provide an insufficient benefit, or if Indemnitee is covered by similar insurance
maintained by a parent or subsidiary of the Company. 
  
 8.
Severability. Nothing in this Agreement is intended to require or shall be construed as requiring the Company to do or fail to do any act in violation of applicable law. The Company’s inability, pursuant to court order, to perform
its obligations under this Agreement shall not constitute a breach of this Agreement. The provisions of this Agreement shall be severable as provided in this Section 8. If this Agreement or any portion hereof shall be invalidated on any ground by
any court of competent jurisdiction, then the Company shall nevertheless indemnify Indemnitee to the full extent permitted by any applicable portion of this Agreement that shall not have been invalidated, and the balance of this Agreement not so
invalidated shall be enforceable in accordance with its terms. 
  
 9. Exceptions. Any other provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the terms of this Agreement: 
  
 (a) Claims Initiated by Indemnitee. To indemnify or advance expenses to Indemnitee with respect to proceedings
or claims initiated or brought voluntarily by Indemnitee and not by way of defense, except with respect to proceedings brought to establish or enforce a right to indemnification under this Agreement or any other statute or law or otherwise as
required under Section 145 of the Delaware General Corporation Law, but such indemnification or advancement of expenses may be provided by the Company in specific cases if the Board of Directors finds it to be appropriate; 
  
 (b) Lack of Good Faith. To indemnify Indemnitee for any
expenses incurred by Indemnitee with respect to any proceeding instituted by Indemnitee to enforce or interpret this 
  

 -5- 

 Agreement, if a court of competent jurisdiction determines that each of the material assertions made by Indemnitee in
such proceeding was not made in good faith or was frivolous; 
  
 (c) Insured Claims. To indemnify Indemnitee for expenses or liabilities of any type whatsoever (including, but not limited to, judgments, fines, ERISA excise taxes or penalties, and amounts paid in settlement) to the extent
such expenses or liabilities have been paid directly to Indemnitee by an insurance carrier under a policy of officers’ and directors’ liability insurance maintained by the Company; or 
  
 (d) Claims under Section 16(b). To indemnify Indemnitee for
expenses or the payment of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 16(b) of the Securities Exchange Act of 1934, as amended, or any similar successor statute. 
  
 10. Construction of Certain Phrases. 
  
 (a) For purposes of this Agreement, references to the
“Company” shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would
have had power and authority to indemnify its directors, officers, and employees or agents, so that if Indemnitee is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such
constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, Indemnitee shall stand in the same position under the provisions of this Agreement with respect to the
resulting or surviving corporation as Indemnitee would have with respect to such constituent corporation if its separate existence had continued. 
  
 (b) For purposes of this Agreement, references to “other enterprises” shall include employee benefit plans; references to
“fines” shall include any excise taxes assessed on Indemnitee with respect to an employee benefit plan; and references to “serving at the request of the Company” shall include any service as a director, officer,
employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants, or beneficiaries; and if Indemnitee acted in good faith and in a
manner Indemnitee reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan, Indemnitee shall be deemed to have acted in a manner “not opposed to the best interests of the Company”
as referred to in this Agreement. 
  
 11. Attorneys’
Fees. In the event that any action is instituted by Indemnitee under this Agreement to enforce or interpret any of the terms hereof, Indemnitee shall be entitled to be paid all court costs and expenses, including reasonable attorneys’
fees, incurred by Indemnitee with respect to such action, unless as a part of such action, the court of competent jurisdiction determines that each of the material assertions made by Indemnitee as a basis for such action were not made in good faith
or were frivolous. In the event of an action instituted by or in the name of the Company under this Agreement or to enforce or interpret any of the terms of this Agreement, Indemnitee shall be entitled to be paid all court costs and expenses,
including attorneys’ fees, incurred by Indemnitee in defense of such action (including with respect to 
  

 -6- 

 Indemnitee’s counterclaims and cross-claims made in such action), unless as a part of such action the court
determines that each of Indemnitee’s material defenses to such action were made in bad faith or were frivolous. 
  
 12. Miscellaneous. 
  
 (a) Governing Law. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall
be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles of conflict of law. 
  
 (b) Entire Agreement; Enforcement of Rights. This Agreement sets forth the entire agreement and understanding of the parties relating to the
subject matter herein and merges all prior discussions between them. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing signed by the parties to this Agreement.
The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party. 
  
 (c) Construction. This Agreement is the result of negotiations between and has been reviewed by each of the parties hereto and their
respective counsel, if any; accordingly, this Agreement shall be deemed to be the product of all of the parties hereto, and no ambiguity shall be construed in favor of or against any one of the parties hereto. 
  
 (d) Notices. Any notice, demand or request required or
permitted to be given under this Agreement shall be in writing and shall be deemed sufficient when delivered personally or sent by telegram or fax, or forty-eight (48) hours after being deposited in the U.S. mail, as certified or registered mail,
with postage prepaid, and addressed to the party to be notified at such party’s address as set forth below or as subsequently modified by written notice. 
  

(e) Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which
together shall constitute one instrument. 
  
 (f) Successors
and Assigns. This Agreement shall be binding upon the Company and its successors and assigns, and inure to the benefit of Indemnitee and Indemnitee’s heirs, legal representatives and assigns. 
  
 (g) Subrogation. In the event of payment under this Agreement,
the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all documents required and shall do all acts that may be necessary to secure such rights and to enable the Company to
effectively bring suit to enforce such rights. 
  
 [Signature
Page Follows] 
  

 -7- 

 The parties hereto have executed this Agreement as of the day and year set forth on the first page of
this Agreement. 
  
  

	 RITA Medical Systems, Inc.

	
	 By:                                      
                                        
      

	
	 Title:                                     
                                        
   

	
	 Address:    967 N. Shoreline Blvd.
                    Mountain View,
CA 94043

	 

  

	 AGREED TO AND ACCEPTED:

	
	 ___________________________________________

	 (Signature)

	
	 Address:    

	 

  

 -8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}]]